Aravive (ARAV) 10-K 27 Mar 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Mar. 16, 2020	Jun. 28, 2019
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Trading Symbol	ARAV
Title of 12(b) Security	Common stock, par value $0.0001 per share
Security Exchange Name	NASDAQ
Entity Registrant Name	Aravive, Inc.
Entity Central Index Key	0001513818
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		15,015,932
Entity Interactive Data Current	Yes
Entity File Number	001-36361
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	26-4106690
Entity Address, Address Line One	River Oaks Tower
Entity Address, Address Line Two	3730 Kirby Drive, Suite 1200
Entity Address, City or Town	Houston
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	77098
City Area Code	936
Local Phone Number	355-1910
Document Annual Report	true
Document Transition Report	false
Entity Public Float			$ 45,315,713
Documents Incorporated by Reference	Documents incorporated by reference: None

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 65,134	$ 56,992
Prepaid expenses and other current assets	3,079	1,038
Total current assets	68,213	58,030
Restricted cash	2,423	2,396
Property and equipment, net	1,808	32
Operating lease right-of-use assets	8,697
Build-to-suit lease asset, net		8,651
Intangible asset, net	219	341
Other assets	761	20
Total assets	82,121	69,470
Current liabilities
Accounts payable	1,078	426
Accrued liabilities	1,497	1,365
Operating lease obligation, current portion	2,393
Deferred revenue		146
Total current liabilities	4,968	1,937
Contingent payable	264	264
Operating lease obligation	7,840
Build-to-suit lease obligation		7,324
Total liabilities	13,072	9,525
Commitments and contingencies
Stockholders' equity
Preferred stock, $0.0001 par value, 5,000,000 shares authorized at December 31, 2019 and December 31, 2018; zero shares issued and outstanding at December 31, 2019 and December 31, 2018
Common stock, $0.0001 par value, 100,000,000 shares authorized at December 31, 2019 and December 31, 2018; 15,001,795 and 11,266,151 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively	2	1
Additional paid-in capital	539,158	510,509
Accumulated deficit	(470,111)	(450,565)
Total stockholders' equity	69,049	59,945
Total liabilities and stockholders’ equity	$ 82,121	$ 69,470

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	15,001,795	11,266,151
Common stock, shares outstanding	15,001,795	11,266,151

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenue
Total revenue	$ 4,753	$ 1,371
Type of Revenue [Extensible List]	us-gaap:GrantMember	us-gaap:GrantMember
Operating expenses
Research and development	$ 12,836	$ 11,075
Write-off of acquired in-process research and development		38,313
General and administrative	13,691	27,395
Total operating expenses	26,527	76,783
Loss from operations	(21,774)	(75,412)
Interest income	1,022	989
Interest expense		(2,429)
Other income (expense), net	2,534	519
Net loss	$ (18,218)	$ (76,333)
Net loss per share- basic and diluted	$ (1.57)	$ (10.64)
Weighted-average common shares used to compute net loss per share- basic and diluted	11,589	7,171

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Beginning Balances at Dec. 31, 2017	$ 82,756	$ 1	$ 456,987	$ (374,232)
Beginning Balances, shares at Dec. 31, 2017		5,989,688
Issuance of common stock upon exercise of options	$ 35		35
Issuance of common stock upon exercise of options, shares	3,643	3,643
Issuance of common stock under employee benefit plans	$ 17		17
Issuance of common stock under employee benefit plans, shares		130,905
Stock-based compensation	16,139		16,139
Issuance of common stock for the merger transaction	37,331		37,331
Issuance of common stock for the merger transaction, shares		5,141,915
Net loss	(76,333)			(76,333)
Ending Balances at Dec. 31, 2018	59,945	$ 1	510,509	(450,565)
Ending Balances, shares at Dec. 31, 2018		11,266,151
Issuance of common stock in public offering, net of issuance costs of $351	25,128	$ 1	25,127
Issuance of common stock in public offering, net of issuance costs of $351, shares		3,633,334
Cumulative-effect adjustment to equity due to adoption of ASU 2016-02	(1,328)			(1,328)
Issuance of common stock upon exercise of options	$ 95		95
Issuance of common stock upon exercise of options, shares	39,686	39,686
Issuance of common stock under employee benefit plans	$ 28		28
Issuance of common stock under employee benefit plans, shares		62,624
Stock-based compensation	3,399		3,399
Net loss	(18,218)			(18,218)
Ending Balances at Dec. 31, 2019	$ 69,049	$ 2	$ 539,158	$ (470,111)
Ending Balances, shares at Dec. 31, 2019		15,001,795

Condensed Statements of Stockho

Condensed Statements of Stockholders' Equity (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Statement Of Stockholders Equity [Abstract]
Net Issuance costs	$ 351

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities
Net loss	$ (18,218)	$ (76,333)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization	498	1,060
Write-off of acquired in-process research & development		38,313
Stock-based compensation expense	3,399	16,139
Changes in assets and liabilities, net of acquisition
Prepaid expenses and other assets	(2,782)	(224)
Accounts payable	652	(1,744)
Deferred revenue	(146)	(1,371)
Accrued and other liabilities	(484)	(5,097)
Net cash used in operating activities	(17,081)	(29,257)
Cash flows from investing activities
Purchase of property and equipment		(33)
Cash paid to acquire in-process research & development		(2,076)
Cash acquired in the merger transaction		5,277
Net cash provided by investing activities		3,168
Cash flows from financing activities
Inducement on build-to-suit lease obligation		1,896
Proceeds from issuance of common stock, net of issuance costs	25,127
Proceeds from issuance of common stock in connection with employee benefit plans and exercise of stock options	123	52
Net cash provided by financing activities	25,250	1,948
Net increase (decrease) in cash, cash equivalents and restricted cash	8,169	(24,141)
Cash, cash equivalents and restricted cash at beginning of period	59,388	83,529
Cash, cash equivalents and restricted cash at end of period	67,557	59,388
Supplemental disclosure of noncash items
Issuance of common stock for the merger transaction		$ 37,331
Property and equipment recorded upon adoption of ASU 2016-02	$ 2,151

Formation and Business of the C

Formation and Business of the Company	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Formation and Business of the Company	1. Formation and Business of the Company Aravive, Inc. (“Aravive” or the “Company”) was incorporated on December 10, 2008 in the State of Delaware. Aravive is a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. Prior to the merger with Aravive Biologics, Inc. (the “Merger”), Aravive (then known as Versartis, Inc.) was an endocrine-focused biopharmaceutical company that was developing a long-acting recombinant human growth hormone for the treatment of growth hormone deficiency. The “Company” refers to Aravive as a combined company following the completion of the Merger with Aravive Biologics, Inc. (“Private Aravive”). The Merger became effective on October 12, 2018. On October 15, 2018, Versartis, Inc. changed its name to Aravive, Inc. The Company’s lead product candidate, AVB-500 (previously referred to as AVB-S6-500), is an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway by binding GAS6. By capturing serum GAS6, AVB-500 starves the AXL pathway of its signal, potentially halting the biological programming that promotes disease progression. AXL receptor signaling plays an important role in multiple types of malignancies by promoting metastasis, cancer cell survival, resistance to treatments, and immune suppression. The GAS6-AXL signaling pathway also plays a significant role in fibrogenesis. The Company’s current development program benefits from the availability of a proprietary serum-based biomarker that we expect will help accelerate drug development by allowing the Company to select a pharmacologically active dose. In the Company’s completed Phase 1 clinical trial with our clinical lead product candidate, AVB-500, the Company has demonstrated proof of mechanism for AVB-500 in neutralizing GAS6. Importantly, AVB-500 had a favorable safety profile preclinically and in the first in human trial in healthy volunteers. In December 2018, the Company initiated the Phase 1b portion of a Phase 1b/2 clinical trial of AVB-500 combined with standard of care therapies in patients with platinum-resistant ovarian cancer and are currently enrolling the expansion cohort in the Phase 1b. In August 2018, the U.S. Food and Drug Administration (FDA) granted fast track designation to AVB-500 for platinum-resistant recurrent ovarian cancer. In January 2020, the Company announced that the FDA has cleared our Investigational New Drug (IND) application for investigation of AVB-500, in the treatment of our second oncology indication, clear cell renal cell carcinoma (ccRCC). As the Company advances its clinical programs, the Company is in close contact with its CROs and clinical sites and is assessing the With the recent and rapidly evolving impact of COVID-19 on patient recruitment in clinical trials and considering patient safety and trial integrity, Aravive has decided to amend its clear cell renal cell carcinoma (ccRCC) trial to initiate treatment at a higher dose given the safety profile seen with the 15 mg/kg dosing cohort of the platinum resistant ovarian cancer (PROC) trial and the initiation of the 20 mg/kg dosing cohort. While this may delay first patient dosing, the overall timelines may not be significantly impacted given the higher starting dose, assuming the COVID-19 situation does not interfere with ongoing clinical studies. The Company will pause new enrollment in its IgA nephropathy (IgAN) trial until the risk of unnecessary exposure of patients to COVID-19 is decreased. In July 2016, Private Aravive was approved for a $20 million Product Development Award from the Cancer Prevention and Research Institute of Texas (“CPRIT Grant”). The CPRIT Grant was expected to allow Private Aravive to develop the product candidate referenced above through clinical trials. The CPRIT Grant was effective as of June 1, 2016 and terminated on November 30, 2019. Private Aravive’s royalty and other obligations, including its obligation to repay the disbursed grant proceeds under certain circumstances, survive the termination of the agreement. The CPRIT Grant is subject to customary CPRIT funding conditions including a matching funds requirement where Private Aravive matched 50% of funding from the CPRIT Grant. Consequently, Private Aravive was required to raise $10.0 million in matching funds over the three-year project. Private Aravive has raised all its required $10.0 million in matching funds. Private Aravive’s award from CPRIT requires it to pay CPRIT a portion of its revenues from sales of certain products, or received from its licensees or sublicensees, at tiered percentages of revenue in the low- to mid-single digits until the aggregate amount of such payments equals 400% of the grant award proceeds, and thereafter at a rate of less than one percent for as long as Private Aravive maintains government exclusivity. In addition, the grant contract also contains a provision that provides for repayment to CPRIT of the full amount of the grant proceeds under certain specified circumstances involving relocation of Private Aravive’s principal place of business outside Texas. As consideration for the rights granted as part of a license agreement with Stanford University, Private Aravive is obligated to pay yearly license fees and milestone payments, and a royalty based on net sales of products covered by the patent-related rights. More specifically, Private Aravive is obligated to pay Stanford University (i) annual license payments (ii) milestone payments of up to an aggregate of $1,000,000 upon achievement of clinical and regulatory milestones, and (iii) royalties equal to a percentage (in the low single digits) of net sales of licensed products; provided that the annual license payments made will offset (and be credited against) any royalties due in such license year. In the event of a sublicense to a third party of any rights based on the patents that are solely owned by Stanford University, Private Aravive is obligated to pay royalties to Stanford University equal to a percentage of what Private Aravive would have been required to pay to Stanford University had it sold the products under sublicense itself. In addition, in such event it is required to pay to Stanford University a percent of sublicensing income. In the event of a termination, Private Aravive will be obligated to pay all amounts that accrued prior to such termination. In connection with the completion of the Merger, on October 15, 2018, the amended and restated certificate of incorporation of the Company was amended to effect, at 12:01 a.m. Eastern Time on October 16, 2018, a reverse split of Company Common Stock at a ratio of 1-for-6 (the “Amended Certificate”). All share and per share amounts in the consolidated financial statements have been retroactively adjusted for all periods presented to give effect to the reverse split, including reclassifying an amount equal to the reduction in par value to additional paid-in capital. The Reverse Split affected all issued and outstanding shares of Common Stock, as well as Common Stock underlying stock options and restricted stock units outstanding immediately prior to the effectiveness of the Reverse Split.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation and Use of Estimates The accompanying consolidated financial statements have been prepared in accordance with GAAP. The preparation of the accompanying consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The accompanying financial statements are consolidated for the years ended December 31, 2019 and 2018 and include the accounts of Aravive, Inc. and its wholly-owned subsidiaries, Versartis Cayman Holdings Company, incorporated in 2014, Versartis GmbH, incorporated in 2015 and Private Aravive, incorporated in 2007. After 2015, the Cayman and GmbH subsidiaries became dormant. In 2019, the Cayman and GmbH subsidiaries were liquidated in their respective countries and no longer exist as of December 31, 2019. All intercompany accounts and transactions have been eliminated. The U.S. dollar is the functional currency for all of the Company's subsidiaries and consolidated operations. Liquidity and Capital Resources Since inception, the Company has incurred net losses and negative cash flows from operations. At December 31, 2019, the Company had an accumulated deficit of $470.1 million and working capital of $63.3 million. Since inception, the Company has incurred net losses and negative cash flows from operations. The Company expects to continue to incur losses from costs related to the development of AVB-500 and related administrative activities for the foreseeable future. As of December 31, 2019, the Company had a cash and cash equivalents balance of $65.1 million consisting of cash and investments in highly liquid U.S. money market funds. While the Company believes that its existing cash and cash equivalents will be sufficient to sustain operations for at least the next 12 months from the issuance of these financial statements, based on its current business plan, the Company will need to obtain additional financing to advance our clinical development program to later stages of development and commercialize our clinical product candidate. Although management has been successful in raising capital in the past, there can be no assurance that the Company will be successful or that any needed financing will be available in the future at terms acceptable to the Company. Correction of Quarterly Information During the fourth quarter ended December 31, 2018, the Company determined that the amount related to the inducement on build-to-suit lease obligation as reflected within one line in the investing activities section of the unaudited consolidated statement of cash flows for the three-, six-, and nine-month periods ended March 31, 2018, June 30, 2018, and September 30, 2018, respectively, filed on Form 10-Q, should have been classified as cash flows provided from financing activities. There is no impact to the consolidated statements of operations and comprehensive loss or consolidated balance sheets for any of these periods. The Company evaluated the effect of this misclassification and concluded it was not material to any of its previously issued unaudited consolidated financial statements. Upon revision, cash flows from investing activities for the three-, six-, and nine-month periods ended March 31, 2018, June 30, 2018, and September 30, 2018, decreased by $1.5 million, $1.9 million, and $1.9 million, respectively and cash flows from financing activities for the respective periods increased by $1.5 million, $1.9 million, and $1.9 million, respectively. This adjustment had no impact to the Company’s financial position, results of operations or cash flows as of and for the year ended December 31, 2018. Segments The Company operates in one segment. Management uses one measurement of profitability and does not segregate its business for internal reporting. All long-lived assets are maintained in the United States of America. Concentration of c r Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. All of the Company’s cash and cash equivalents are held at several financial institutions that management believes are of high credit quality. Such deposits may exceed federally insured limits. Risk and Uncertainties The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company’s potential drug candidates, uncertainty of market acceptance of the Company’s products, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals and sole source suppliers. Products developed by the Company require clearances from the U.S. Food and Drug Administration (“FDA”), the Pharmaceuticals Medicines and Devices Agency (“PMDA”), or other international regulatory agencies prior to commercial sales. There can be no assurance that the products will receive the necessary clearances. If the Company is denied clearance, clearance is delayed or the Company is unable to maintain clearance, it could have a material adverse impact on the Company. The Company expects to incur substantial operating losses for the next several years and will need to obtain additional financing in order to launch and commercialize any product candidates for which it receives regulatory approval. Cash and c e The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. At December 31, 2019 and 2018 the Company’s cash and cash equivalents were held in multiple institutions within the United States and included deposits in money market funds which were unrestricted as to withdrawal or use. Restricted cash consists of a letter of credit to secure the Company’s obligations under the right-of-use lease. Property and e Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, generally between three and five years. Leasehold improvements are amortized on a straight-line basis over the lesser of their useful life or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the consolidated balance sheets and any resulting gain or loss is reflected in operations in the period realized. Leases The Company adopted ASC 842 on January 1, 2019. For the periods prior to January 1, 2019, the Company’s leases were accounted for under ASC 840. The Company leases all of its office space in conducting its business. At inception, the Company determines whether an agreement represents a lease and at commencement the Company evaluates each lease agreement to determine whether the lease is an operating or financing lease. As described below under "Recent Accounting Pronouncements”, the Company adopted the Financial Accounting Standards Board Accounting Standards Update, or ASU, "Leases," or ASU 2016-02. The Company elected to adopt the standard on January 1, 2019 using the alternative transition method provided by ASU 2018-11 whereby the Company recorded right-of-use (“ROU”) assets and lease liabilities for its existing leases as of January 1, 2019, as well as a cumulative-effect adjustment to accumulated deficit of initially applying the new standard as of January 1, 2019. The new standard provides a number of optional practical expedients in transition. The Company has elected the practical expedients to not reassess its prior conclusions about lease identification under the new standard, to not reassess lease classification, and to not reassess initial direct costs. The Company has elected the practical expedient allowing the use-of-hindsight which doesn’t require the Company to reassess the lease term of its leases based on all facts and circumstances through the effective date. The new guidance also provides practical expedients for ongoing lease accounting. The Company has elected the recognition exemption for short-term lease for all leases that qualify. Under this exemption, the Company will not recognize ROU assets or lease liabilities on the consolidated balance sheet for those leases that qualify as a short-term lease, which includes not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in transition. The Company has also elected the practical expedient to not separate lease and non-lease components for all equipment and real-estate leases. With the adoption of ASU 2016-02, the Company recorded an operating lease right-of-use asset and an operating lease obligation on the consolidated balance sheet. ROU assets represent the Company’s ROU of the underlying asset for the lease term and the lease obligation represents the Company’s commitment to make the lease payments arising from the lease. ROU obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term and ROU assets are calculated as the lease liability, adjusted by unamortized initial direct costs, unamortized lease incentives received, cumulative deferred or prepaid lease payments, and accumulated impairment losses. As the Company’s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the adoption date in determining the present value of lease payments. The lease term may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms. Variable lease costs such as common area costs and property taxes are expensed as incurred. Variable lease costs and short-term lease payments not included in the lease liability are classified within operating activities in the consolidated statements of cash flows. For all lease agreements the Company has combined lease and nonlease components. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. These expenses are recognized within operating expenses in the consolidated statements of operations. The Company accounts for the sublease with EVA as an operating lease. The Company reviews the right-of-use asset recorded associated with the sublease for impairment whenever events or changes in circumstances indicate that the carrying amount of the right-of-use asset may not be recoverable. Recoverability is measured if the lease cost for the term of the sublease exceeds the anticipated sublease income for the same period on an undiscounted basis and the Company shall treat this circumstance as an indicator that the carrying amount of the right-of-use asset may not be recoverable. There have been no such impairments of right-of-use assets during the year ended December 31, 2019. Prior to the Company’s adoption of ASU 2016-02, when the Company’s lease agreements contained renewal options, tenant improvement allowances, rent holidays and rent escalation clauses, the Company recorded a deferred rent asset or liability equal to the difference between the rent expense and the future minimum lease payments due. The lease expense related to operating leases was recognized on a straight-line basis in the consolidated statements of operations over the term of each lease. Impairment of Long-Lived Assets The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by the comparison of the carrying amount to the future net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value (i.e. determined through estimating projected discounted future net cash flows or other acceptable methods of determining fair value) arising from the asset. There have been no such impairments of long-lived assets during the years ended December 31, 2019 and 2018. Fair Value of Financial Instruments The carrying value of the Company’s cash and cash equivalents, restricted cash, accounts payable and accrued liabilities approximate fair value due to the short-term nature of these items. Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities; Level 2 Inputs other than quoted prices included within Level 1 that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and Level 3 Unobservable inputs that are supported by little or no market activity for the related assets or liabilities. The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Company’s financial instruments consist of Level 1 assets as of December 31, 2019 and 2018. Level 1 securities are comprised of highly liquid money market funds. Preclinical and Clinical Trial Accruals The Company’s clinical trial accruals are based on estimates of patient enrollment and related costs at clinical investigator sites as well as estimates for the services received and efforts expended pursuant to contracts with multiple research institutions and clinical research organizations (“CROs”) that conduct and manage clinical trials on the Company’s behalf. The Company estimates preclinical and clinical trial expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on its behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of patient enrollment and activity expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered. Research and d Research and development costs are charged to operations as incurred. Research and development costs include, but are not limited to, payroll and personnel expenses, laboratory supplies, consulting costs, external research and development expenses and allocated overhead, including rent, equipment depreciation, and utilities. Costs to acquire technologies to be used in research and development that have not reached technological feasibility and have no alternative future use are expensed to research and development costs when incurred. Income t The Company accounts for income taxes under the asset and liability approach. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability and is measured at the largest amount of benefit that is greater than percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i) the factors underlying the sustainability assertion have changed and (ii) the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available. Stock-Based c For stock options granted to employees, the Company recognizes compensation expense for all stock-based awards based on the grant-date estimated fair value. The value of the portion of the award that is ultimately expected to vest is recognized as expense ratably over the requisite service period. The fair value of stock options is determined using the Black-Scholes option pricing model. The determination of fair value for stock-based awards on the date of grant using an option pricing model requires management to make certain assumptions regarding a number of complex and subjective variables. Stock-based compensation expense related to stock options granted to nonemployees is recognized based on the fair value of the stock options, determined using the Black-Scholes option pricing model, as they are earned. The awards generally vest over the time period the Company expects to receive services from the nonemployee. Comprehensive Loss Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. Specifically, the Company includes cumulative foreign currency translation adjustments and net unrealized gains. There was no difference between net loss and comprehensive loss for all periods presented. Net Loss per Share of Common Stock Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, stock options and restricted stock units are considered to be potentially dilutive securities. Because the Company has reported a net loss for the years ended December 31, 2019 and 2018, diluted net loss per common share is the same as basic net loss per common share for those periods. In-process Research & Development I n-process research and development, or IPR&D, was recorded at its relative fair value using a discounted cash flow model and was assigned to acquired research and development assets that were not fully developed as of the completion of the Merger. IPR&D acquired in an asset purchase is capitalized on the Company’s consolidated balance sheet at its acquisition-date fair value if the acquired IPR&D has alternative future use. For the IPR&D that was acquired from the Merger it was determined that the IPR&D had no alternative future use and therefore it was expensed immediately following the Merger. Fair value measurement was classified as Level 3 under the fair value hierarchy. Intangible Asset Intangible assets consist of an assembled workforce which was acquired as part of the Merger. Intangible assets with definite lives are amortized based on their pattern of economic benefit over their estimated useful lives and reviewed periodically for impairment. The estimated useful life of the assembled workforce is 3 years. Revenue Recognition The Company’s sole source of revenue for 2019 and 2018 was grant revenue related to the CPRIT Grant, which is being recognized when qualifying costs are incurred and there is reasonable assurance that the conditions of the award have been met for collection. Proceeds received prior to the costs being incurred or the conditions of the award being met are recognized as deferred revenue until the services are performed and the conditions of the award are met. Funds received are reflected in deferred revenue as a liability until revenue is earned. Grant revenue is recognized when qualifying costs are incurred. As of December 31, 2019, the Company had an unbilled receivable from CPRIT of $1.6 million, which is reflected in prepaid expenses and other current assets on the accompanying consolidated balance sheet. As of December 31, 2018, the Company had deferred revenue of $0.1 million. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective is not expected to have a material impact on the Company’s financial position or results of operations upon adoption. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) As a result of the adoption of ASC 842 on January 1, 2019, the Company derecognized $8.6 million for the existing asset; $7.3 million for the obligation and $1.3 million to the opening balance of the accumulated deficit. The existing asset and obligation on the consolidated balance sheet resulted from the build-to-suit lease arrangement at 1020 Marsh Road, Menlo Park, California or the 1020 Space, which did not meet the criteria for “sale-leaseback” treatment at the time construction was completed in 2017, and the Company has applied the general lessee transition guidance to this lease. Based on the Company’s assessment of the 1020 Space, qualifies as an operating lease under ASC 842. Additionally, as a result of adoption of ASC 842, the Company recognized operating lease ROU assets of approximately $10.4 million, $2.2 million of leasehold improvements, an operating lease obligation of $12.6 million and derecognition of deferred rent of $0.1 million as of January 1, 2019. In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718) - Improvements to Nonemployee Share-Based Payment Accounting . This amendment provides additional guidance related to share-based payment transactions for acquiring goods or services from nonemployees. The guidance will be effective for the Company for fiscal years beginning after December 15, 2018, including the interim periods within that fiscal year. The Company has adopted this new guidance as of January 1, 2019, which had no material impact on the Company’s consolidated financial statements. Not-For-Profit Entities (Topic 958): Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made The Company has adopted this guidance as of January 1, 2019 which had no material impact to its consolidated financial statements. In May 2017, the FASB issued, ASU-2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting . This guidance clarifies when changes to the terms and conditions of share-based awards must be accounted for as modifications. The guidance does not change the accounting treatment for modifications. The guidance, which became effective on January 1, 2018, has not had a material impact on the Company’s consolidated financial statements. In January 2017, the FASB issued, ASU-2017-01, Business Combinations (Topic 805) – Clarifying the Definition of a Business. In November 2016, the FASB issued, ASU-2016-18, Statement of Cash Flows (Topic 230) - Restricted Cash

Balance Sheet Components

Balance Sheet Components	12 Months Ended
	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Balance Sheet Components	3. Balance Sheet Components Prepaid expenses and other current assets (in thousands) December 31, 2019 2018 Preclinical and clinical $ 531 $ 416 Lease receivable 900 606 Unbilled receivable from CPRIT 1,604 — Other 44 16 Total $ 3,079 $ 1,038 Property and equipment, net (in thousands) December 31, 2019 2018 Equipment and furniture $ 1,442 $ 1,442 Buildings, leasehold and building improvements 2,674 134 4,116 1,576 Less: Accumulated depreciation and amortization (2,308 ) (1,544 ) Property and equipment, net $ 1,808 $ 32 Depreciation expense was approximately $0.4 million and $1.1 million for the years ended December 31, 2019 and 2018, respectively. Intangible asset, net (in thousands) December 31, 2019 2018 Assembled workforce $ 366 $ 366 366 366 Less: Accumulated amortization (147 ) (25 ) Intangible asset, net $ 219 $ 341 Amortization expense is expected to be approximately $0.1 million in each year over the next 1.8 years. Accrued liabilities (in thousands) December 31, 2019 2018 Payroll and related $ 1,248 $ 509 Preclinical and clinical 5 563 Professional services 32 — Other 212 293 Total $ 1,497 $ 1,365

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	4. Fair Value Measurements The Company’s financial instruments consist principally of cash and cash equivalents, prepaid expenses, foreign currency exchange contracts, accounts payable and accrued liabilities. The remaining financial instruments are reported on the Company’s consolidated balance sheets at amounts that approximate current fair value. The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): Fair Value Measurements at December 31, 2019 Total Level 1 Assets Money market funds $ 63,691 $ 63,691 Fair Value Measurements at December 31, 2018 Total Level 1 Assets Money market funds $ 48,389 $ 48,389 The Company recognizes transfers between levels of the fair value hierarchy as of the end of the reporting period. There were no transfers within the hierarchy during the years ended December 31, 2019 or 2018.

Leases

Leases	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Leases	5. Leases The Company adopted ASC 842 as of January 1, 2019, using the modified retrospective approach and therefore prior year financial statements were not recast under the new standard. In March 2017, the Company entered into an operating facility lease agreement for approximately 34,500 rentable square feet located at the 1020 Space. The lease commenced in August 2017 for a period of 87 months with one renewal option for a five-year term. The Company did not include the renewal option period as the Company determined it was not reasonably certain the lease would be renewed as of the modification date. In October 2018, the Company executed a sublease agreement in Palo Alto, California for approximately 4,240 square feet for office space. The rental term of the sublease commenced on October 30, 2018 and expires August 31, 2020. The Company’s rent expense including both short-term and variable lease components of $0.5 million associated with the facility leases was $2.5 million for the year ended December 31, 2019. Cash paid for amounts included in the measurement of lease obligations for operating cash flows from operating leases for 2019 was $2.7 million. As of December 31, 2019, the Company’s operating leases had a weighted average remaining lease term of 4.6 years and a weighted average discount rate of 7.75%, which approximates the Company’s incremental borrowing rate. As of December 31, 2019, minimum lease payments under non-cancelable operating leases by period were expected to be as follows (in thousands): Year Ending December 31, 2020 $ 2,668 2021 2,618 2022 2,697 2023 2,777 2024 2,373 Total future minimum lease payments 13,133 Less: discount (2,900 ) Total lease liabilities $ 10,233 As of December 31, 2018, minimum lease payments under non-cancelable operating leases by period were expected to be as follows (in thousands): Year Ending December 31, 2019 $ 2,652 2020 2,668 2021 2,618 2022 2,697 2023 2,777 Thereafter 2,373 $ 15,785 1020 Marsh Sublease In August 2018, the Company entered into an operating sublease agreement with EVA Automation, Inc. (“EVA”) for the 1020 Space referenced above. The 1020 Space Sublease commenced on October 1, 2018 for 73 months. EVA is entitled to an abatement of base rent of approximately $0.9 million for the first five full calendar months of the term of the sublease. Lease income associated with this sublease is recorded in other income in the accompanying consolidated statements of operations. The Company has recorded lease income associated with this sublease of approximately $2.5 million and $0.6 million for 2019 and 2018 respectively. During 2019, cash received from EVA was $2.3 million, which amount was included in prepaid expenses and other assets for operating cash flows. Future base rent and additional rent EVA shall pay to the Company over the sublease term as of December 31, 2019, are as follows (in thousands): Year Ending December 31, 2020 $ 2,563 2021 2,628 2022 2,695 2023 2,764 2024 2,355 $ 13,005 Build-to-Suit Lease In March 2017, the Company entered into an operating facility lease agreement for approximately 34,500 rentable square feet located at 1020 Marsh Road, Menlo Park, California and for approximately 17,400 rentable square feet located at 1060 Marsh Road. In September 2017, the Company opted out of its intent to occupy 1060 Marsh Road. The Company began occupying 1020 Marsh Rd in August 2017. The lease has a term of 86 months from the commencement date as defined in the lease agreement with the Company’s option to extend the term of the lease for an additional five years. The Company is obligated to make lease payments totaling approximately $20.0 million over the initial term of the lease. In connection with this lease, the landlord is providing a tenant improvement allowance of approximately $1.9 million for the 1020 Space, for costs associated with the design, development and construction of the Company’s improvements. The Company is obligated to fund all costs incurred in excess of the tenant improvement allowance. The Company provided the Landlord with a letter of credit to secure its obligations under the lease in the initial amount of approximately $2.4 million, reported as restricted cash on the consolidated balance sheets which is subject to reductions in future years if certain financial hurdles are met. Under the terms of the lease agreement, the Company has indemnified the landlord during the construction period. Accordingly, for accounting purposes, the Company has concluded that it is the deemed owner of the building during the construction period and the Company capitalized approximately $8.9 million within build-to-suit lease asset and recognized an $7.3 million corresponding build-to-suit lease obligation in non-current liabilities in the consolidated balance sheet as of December 31, 2018. Of the $8.9 million, approximately $3.5 million has been recorded as a build-to-suit asset related to construction costs incurred by the Company as of December 31, 2018. Rent expense was $0.3 million for the year ended December 31, 2018.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2019
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	6. Commitments and Contingencies Purchase Commitments The Company conducts research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with contract manufacturing organizations and contract research organizations. The Company had contractual arrangements with these organizations including license agreements with milestone obligations and service agreements with obligations largely based on services performed. In the normal course of business, the Company enters into various firm purchase commitments related to certain preclinical and clinical studies. Contingencies In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. Indemnification In accordance with the Company’s amended and restated Certificate of Incorporation and amended and restated bylaws, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company’s request in such capacity. There have been no claims to date and the Company has a director and officer insurance policy that may enable it to recover a portion of any amounts paid for future claims. Litigation The Company may from time to time be involved in legal proceedings arising from the normal course of business. There are no pending or threatened legal proceedings as of December 31, 2019. Contingent payable As part of the Merger, the Company acquired a settlement that Private Aravive entered into with former creditors in 2014 pursuant to which Private Aravive had agreed to make an initial 7.5% cash payment to the creditors with the remainder contingent on future milestone payments, or Contingent Payments, until full repayment of the payables is made. The contingent Payments are to be made from the proceeds received by Private Aravive from any future licensing transactions. The Contingent Payments will be distributed on a pro rata basis with other secured creditors and will be made from at least 10% of any proceeds from any future licensing transactions. The proceeds from any future licensing transactions will be held in an escrow account which will be administered by an independent third party. The creditors agree that the Initial payment and any Contingent Payments represents settlement in full of all outstanding obligations owed to the creditors by Private Aravive and released Private Aravive from all claims. As a result of and in connection with the Merger, the Company determined the fair value of the contingent payable to be approximately $264,000, based upon an appraisal (or valuation) of the assets and liabilities assumed to determine fair values.

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Common Stock	7. Common Stock The Amended and Restated Certificate of Incorporation, authorizes the Company to issue 100,000,000 shares of common stock as of December 31, 2019. Common stockholders are entitled to dividends as and when declared by the Board of Directors, subject to the rights of holders of all classes of stock outstanding having priority rights as to dividends. There have been no dividends declared to date. The holder of each share of common stock is entitled to one vote. The Company had reserved shares of common stock for future issuances as follows: December 31, 2019 2018 Issuance of equity based awards under stock plan 1,391,697 1,201,581 Issuance upon exercise of options under stock plan 1,820,160 1,515,923 Issuance of restricted stock units under stock plan 42,112 117,597 Total 3,253,969 2,835,101 In connection with the completion of the Merger, on October 15, 2018, the amended and restated certificate of incorporation of the Company was amended to effect, at 12:01 a.m. Eastern Time on October 16, 2018, a reverse split of Company Common Stock at a ratio of 1-for-6 (the “Amended Certificate”). The accompanying consolidated financial statements and notes to consolidated financial statements give retroactive effect to the reverse stock split for all periods presented. In December 2019, the Company closed a public offering of its common stock pursuant to which the Company issued 3,633,334 shares of common stock, which included shares issued pursuant to the underwriters’ partial exercise of their over-allotment option, and received net proceeds of approximately $25.1 million, after underwriting discounts, commissions and offering expenses. Related party transaction On December 2, 2019, an entity affiliated with a member of our board of directors, invested approximately $1,000,000 in our public offering and acquired 133,333 shares of common stock in the offering.

Stock Based Awards

Stock Based Awards	12 Months Ended
	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Based Awards	8. Stock Based Awards Equity Incentive Plans The Company’s Board of Directors, or Board, and stockholders approved the 2019 Equity Incentive Plan, or the 2019 Plan, which became effective on September 12, 2019. The 2019 Plan is a successor to and continuation of all prior plans including the Company’s 2014 Equity Incentive Plan and Private Aravive’s 2017 Equity Incentive Plan and the 2010 Equity Incentive Plan, as amended (Prior Plans). As of December 31, 2019, the total number of shares of common stock available for issuance under the 2019 Plan was 1,391,697. In addition, if the shares subject to outstanding stock options or other awards under the Prior Plans: (I) terminate or expire prior to exercise or settlement; (II) are not issued because the award is settled in cash; (III) are forfeited because of failure to vest; (IV) or are reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price, if any, such shares will become available for issuance under the 2019 Plan. Unless the Board provides otherwise, beginning January 1, 2020 with expiration of January 1, 2029, the total number of shares of common stock available for issuance will automatically increase annually on January 1 of each calendar year by 4.5% of the total number of issued and outstanding shares of common stock as of December 31 of the immediately preceding year. The 2019 Plan provides for granting of equity awards to employees, directors and consultants, including incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and performance awards. Activity under the Company’s stock option plans is set forth below: Weighted Average Weighted Remaining Aggregate Average Contractual Intrinsic Number of Exercise Life Value Shares Price (in years) (in thousands) Balances, January 1, 2018 607,511 $ 81.60 Additional shares authorized — — Assumption of option plans associated with the merger 1,183,950 0.44 Options granted — — Restricted stock units granted — — Options exercised (3,643 ) 9.66 Options cancelled (271,895 ) 80.09 Balances, December 31, 2018 1,515,923 18.65 Additional shares authorized — — Options granted 483,328 5.55 Restricted stock units granted — — Options exercised (39,686 ) 2.40 Options cancelled (139,405 ) 81.33 Balances, December 31, 2019 1,820,160 $ 10.70 6.6 $ 18,957 Vested and expected to vest as of December 31, 2019 1,796,997 $ 10.75 6.6 $ 18,778 Exercisable as of December 31, 2019 1,474,782 $ 11.31 6.0 $ 16,311 The intrinsic values of outstanding, vested and exercisable options were determined by multiplying the number of shares by the difference in exercise price of the options and the fair value of the common stock. The intrinsic value of stock options exercised during the years ended December 31, 2019 and 2018, was $0.4 million and none, respectively. The following table summarizes information with respect to stock options outstanding and currently exercisable and vested as of December 31, 2019: Options Exercisable Options Outstanding and Vested Weighted Average Weighted Average Remaining Remaining Range of Number Contractual Number Contractual Exercise Prices Outstanding Life (in Years) Outstanding Life (in Years) $0.06-$0.06 86,867 1.5 86,867 1.5 $0.24-$0.24 621,098 5.4 621,098 5.4 $0.66-$0.90 451,632 7.8 451,632 7.8 $3.54-$5.83 385,673 8.8 110,828 8.8 $5.87-$191.76 274,890 5.8 204,357 5.8 1,820,160 1,474,782 Stock Options Granted to Employees During the year ended December 31, 2019, the Company granted stock options to officers, directors and employees to purchase shares of common stock with a weighted-average grant date fair value of $4.69 per share. The fair value is being expensed over the vesting period of the options, which is usually 4 years on a straight-line basis as the services are being provided. No tax benefits were realized from options and other share-based payment arrangements during the periods. For the year ended December 31, 2018 the fair value assumptions noted below, were all related to the assumed fully vested stock options in accordance with the Merger. No options were granted during the year ended December 31, 2018. As of December 31, 2019, total unrecognized employee stock-based compensation related to stock options granted was $2.0 million, which is expected to be recognized over the weighted-average remaining vesting period of 2.8 years. The fair value of employee stock options was estimated using the Black-Scholes model with the following weighted-average assumptions Year Ended December 31, 2019 2018 Expected volatility 111.0 % 132.0 % Risk-free interest rate 2.4 % 3.0 % Dividend yield 0.0 % 0.0 % Expected life (in years) 6.0 3.3 Determining Fair Value of Stock Options The fair value of each grant of stock options was determined by the Company using the methods and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine. Expected Volatility – Beginning in 2018, the Company had enough historical stock price information in order to value the options assumed in the Merger. The Company continues to utilize our historical stock prices in order to estimate the expected volatility. Risk-Free Interest Rate – The risk-free rate assumption was based on the U.S. Treasury instruments with terms that were consistent with the expected term of the Company’s stock options. Expected Dividend – The expected dividend assumption was based on the Company’s history and expectation of dividend payouts. Expected Term – The expected term of stock options represents the weighted average period the stock options are expected to be outstanding. For option grants that are considered to be “plain vanilla”, the Company has opted to use the simplified method for estimating the expected term as provided by the Securities and Exchange Commission. The simplified method calculates the expected term as the average time-to-vesting and the contractual life of the options. Forfeiture Rate – Forfeitures were estimated based on historical experience. Fair Value of Common Stock – The fair value of the underlying common stock is based upon quoted prices on the Nasdaq Global Select Market. Stock-based compensation expense, net of estimated forfeitures, is reflected in the statements of operations as follows (in thousands): Year Ended December 31, 2019 2018 Operating Expenses Research and development $ 347 $ 2,946 General and administrative 3,052 13,193 Total $ 3,399 $ 16,139 2014 Employee Stock Purchase Plan The board of directors adopted, and the Company’s stockholders approved, the 2014 Employee Stock Purchase Plan, or the ESPP, in March 2014. The ESPP became effective on March 20, 2014. The maximum aggregate number of shares of common stock that may be issued under the ESPP per purchase period is 416 shares (which was adjusted for the reverse stock split that occurred in October 2018). In November 2019, the board of directors adopted a resolution to increase the maximum aggregate number of shares of common stock that may be issued under the ESPP per purchase period 2,500 shares, beginning with the offering period that starts in May 2020. Additionally, the number of shares of common stock reserved for issuance under the ESPP will increase automatically each year, beginning on January 1, 2015 and continuing through and including January 1, 2024, by the lesser of (i) 1% of the total number of shares of our common stock outstanding on December 31 of the preceding calendar year; and (ii) 50,000 shares of common stock (which was adjusted for the reverse stock split that occurred in October 2018). The board of directors may act prior to the first day of any calendar year to provide that there will be no January 1 increase or that the increase will be for a lesser number of shares than would otherwise occur. Shares subject to purchase rights granted under the ESPP that terminate without having been exercised in full will not reduce the number of shares available for issuance under the ESPP. An employee may not be granted rights to purchase stock under the ESPP if such employee (i) immediately after the grant would own stock possessing 5% or more of the total combined voting power or value of the Company’s common stock, or (ii) holds rights to purchase stock under the ESPP that would accrue at a rate that exceeds $25,000 worth of our stock for each calendar year that the rights remain outstanding. The administrator may approve offerings with a duration of not more than 27 months, and may specify one or more shorter purchase periods within each offering. Each offering will have one or more purchase dates on which shares of common stock will be purchased for the employees who are participating in the offering. The administrator, in its discretion, will determine the terms of offerings under the ESPP. The ESPP permits participants to purchase shares of our common stock through payroll deductions with up to 15% of their earnings. The purchase price of the shares will be not less than 85% of the lower of the fair market value of our common stock on the first day of an offering or on the date of purchase. The fair value of the ESPP grants were immaterial for the years ended December 31, 2019 and 2018, respectively. Restricted Stock Units Restricted stock units are shares of common stock which are forfeited if the employee leaves the Company prior to vesting. These stock units offer employees the opportunity to earn shares of the Company’s stock over time, rather than options that give the employee the right to purchase stock at a set price. As a result of these restricted stock units, the Company recognized $1.4 million and $3.2 million, A summary of the Company’s restricted stock activity is presented in the following tables: Weighted Average Number of Grant Date Shares Fair Value Restricted Stock Units Unvested at December 31, 2018 117,597 $ 31.37 Granted — — Vested (59,567 ) 31.37 Forfeited/canceled (15,918 ) 27.16 Unvested at December 31, 2019 42,112 $ 32.97

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes The provision (benefit) for federal income taxes in 2019 and 2018 is as follows (in thousands): December 31, 2019 2018 Current Federal $ — $ — State — — — — Deferred Federal $ — $ — State — — Total deferred tax expense — — Total income tax expense $ — $ — December 31, 2019 2018 United States $ (18,218 ) $ (76,256 ) Foreign (0 ) (77 ) Net loss before provision for income taxes $ (18,218 ) $ (76,333 ) Income tax expense (benefit) in 2019 and 2018 differed from the amount expected by applying the statutory federal tax rate to the income or loss before taxes as summarized below: December 31, 2019 2018 Federal tax benefit at statutory rate 21 % 21 % Change in valuation allowance (23 )% 103 % Section 382 limitation — (109 )% Other non-deductible expenses (1 )% (11 )% Stock based compensation (7 )% (4 ) ASC 842 lease accounting 10 % — Total 0 % 0 % Deferred income taxes reflect the net tax effects of net operating loss and tax credit carryforwards and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s net deferred tax assets at December 31, 2019 and 2018 are as follows (in thousands): December 31, 2019 2018 Net operating loss carry forwards $ 5,869 $ 2,335 Research and development tax credits 90 168 Stock based compensation and other 5,099 5,263 Operating lease obligation 2,149 — Total deferred tax assets 13,207 7,766 Less: Valuation allowance (11,326 ) (7,032 ) Deferred tax liabilities (55 ) (734 ) Operating lease right-of-use assets (1,826 ) — Net deferred tax assets $ — $ — Subsequent to the issuance of the December 31, 2018 consolidated financial statements, the Company corrected the deferred tax asset related to stock based compensation and valuation allowance disclosed in the table above to reflect the appropriate deferred tax asset and valuation allowance amounts as of December 31, 2018. The adjustment decreased the previously reported deferred tax asset and the previously reported valuation allowance by $3.3 million. The correction did not have a material impact on the consolidated financial statements for the year ended December 31, 2018 and did not impact the Company’s Consolidated Balance Sheets, Consolidated Statements of Operations, or Consolidated Statements of Cash Flows as of or for the year ended December 31, 2019. The Company’s accounting for deferred taxes involves the evaluation of a number of factors concerning the realizability of its net deferred tax assets. The Company primarily considered such factors as its history of operating losses, the nature of the Company’s deferred tax assets, and the timing, likelihood and amount, if any, of future taxable income during the periods in which those temporary differences and carryforwards become deductible. At present, the Company does not believe that it is more likely than not that the deferred tax assets will be realized; accordingly, a full valuation allowance has been established and no deferred tax asset is shown in the accompanying consolidated balance sheets. The valuation allowance increased by approximately $4.3 million in 2019 and decreased by $95.1 million in 2018. At December 31, 2019, the Company has net operating loss carryforwards for federal income tax purposes of approximately $27.9 million, of which $23.1 million was generated post December 31, 2017 (after section 382 limitation) and will have no expiration date. The remaining $4.8 million of net operating loss carryforwards begin to expire in 2037. The Company also has federal research and development tax credits of approximately $90 thousand, which begin to expire in 2037. As of December 31, 2019, the Company’s total gross deferred tax assets were $13.2 million. Due to the Company’s lack of earnings history and uncertainties surrounding our ability to generate future taxable income, the net deferred tax assets have been fully offset by a valuation allowance. The deferred tax assets were primarily comprised of federal tax net operating losses and tax credit carryforwards. Utilization of net operating losses and tax credit carryforwards may be limited by the “ownership change” rules, as defined in Section 382 of the Internal Revenue Code (any such limitation, a “Section 382 limitation”). Similar rules may apply under state tax laws. The Company has performed an analysis to determine whether an “ownership change” occurred from inception up to the Private Aravive's acquisition date. Based on this analysis during 2018, management determined that both Versartis, Inc. and Private Aravive did experience ownership changes, which resulted in a significant impairment of the net operating losses and credit carryforwards. In 2019, no additional ownership changes were noted. The Company follows the provisions of FASB Accounting Standards Codification 740-10 (ASC 740-10), Accounting for Uncertainty in Income Taxes. ASC 740-10 prescribes a comprehensive model for the recognition, measurement, presentation and disclosure in consolidated financial statements of uncertain tax positions that have been taken or expected to be taken on a tax return. No liability related to uncertain tax positions is recorded in the consolidated financial statements. At December 31, 2019 and 2018, the Company’s reserve for unrecognized tax benefits is approximately $39 thousand and $72 thousand, respectively. Due to the above-mentioned Section 382 limitation and impairment of tax attributes, in 2018 there was a decrease in prior year unrecognized tax benefits of $3.9 million. Due to the full valuation allowance at December 31, 2018, current adjustments to the unrecognized tax benefit will have no impact on the Company’s effective income tax rate. The Company does not anticipate any significant change in its unrecognized tax benefits within 12 months of this reporting date. The Company includes penalties and interest expense related to income taxes as a component of other expense and interest expense, respectively, as necessary. Because the statute of limitations does not expire until after the net operating loss and credit carryforwards are actually used, the statute is effectively open for all tax years. However, due to the above-mentioned ownership change and impairment of net operating loss and credit carryforwards, only net operating loss and credit carryforwards post-January 14, 2017 are carried forward to future years for federal and state tax purposes. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands): Amount Balance at January 1, 2018 $ 3,934 Gross increase/ (decrease) related to prior year tax positions (3,934 ) Gross increase related to current year positions 72 Reductions to unrecognized tax benefits related to lapsing statute of limitations — Balance at December 31, 2018 $ 72 Gross increase/ (decrease) related to prior year tax positions (72 ) Gross increase related to current year positions 39 Reductions to unrecognized tax benefits related to lapsing statute of limitations — Balance at December 31, 2019 $ 39 All tax years remain open for examination by federal and state tax authorities. The Tax Cuts and Jobs Act ("the Act") was enacted on December 22, 2017. The Act reduces the U.S. federal corporate tax rate from 35% to 21%, requires companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred and creates new taxes on certain foreign sourced earnings. The Company is required to recognize the effect of the tax law changes in the period of enactment, such as determining the estimated transition tax, remeasuring our U.S. deferred tax assets and liabilities at a 21% rate as well as reassessing the net realizability of our deferred tax assets and liabilities. Accordingly, the Company remeasured certain deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future. The provisional amount related to the re-measurement of our deferred tax balance is a reduction of approximately $33 million. Due to the corresponding valuation allowance fully offsetting deferred taxes, there is no income statement impact. In December 2017, the SEC staff issued Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (SAB 118) which allows companies to record provisional amounts during a measurement period not to extend beyond one year of the enactment date. In Q4 2018, the Company completed its analysis within the measurement period in accordance with SAB 118 and found no change to the provisional amount on 2017 tax provision.

Restructuring Plan

Restructuring Plan	12 Months Ended
	Dec. 31, 2019
Restructuring And Related Activities [Abstract]
Restructuring Plan	10. Restructuring Plan In October 2017, the Board of Directors of the Company approved a plan of termination to eliminate a number of positions effective October 20, 2017 (the “Restructuring Plan”), as part of its commitment to reduce costs following the failure of the Phase 3 VELOCITY trial of somavaratan to reach its primary endpoint. The reduction included 45 employees, which represented approximately 62% of its workforce as of October 6, 2017. Affected employees were notified of the Restructuring Plan on October 6, 2017. Simultaneously with the Restructuring Plan the Company established a Severance Benefit Plan (the “Plan”) for affected employees as well as a retention plan for retained employees. The Plan provides payment of severance benefits to affected employees of the Company. The Company granted approximately 907,000 restricted stock units to retained employees with a two year vesting schedule and offered a cash retention bonus of 50% of each retained employees then current base salary, which will be earned and payable subject to continued employment for an additional 12 months. Employee severance costs are accrued when the restructuring actions are probable and estimable. Costs for one-time termination benefits in which the employee is required to render service until termination in order to receive the benefits are recognized ratably over the future service period.

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2019
Compensation And Retirement Disclosure [Abstract]
Employee Benefit Plans	11. Employee Benefit Plans Defined Contribution Plan The Company sponsors a 401(k) Plan, which stipulates that eligible employees can elect to contribute to the 401(k) Plan, subject to certain limitations of eligible compensation. The Company may match employee contributions in amounts to be determined at the Company’s sole discretion. To date, the Company has not made any matching contributions. Severance Benefit Plan & Retention Cash Bonus Simultaneously with the Restructuring Plan, the Company established a Severance Benefit Plan (the “Plan”) for affected employees (See Note 10) as well as a retention plan for retained employees. The Plan provides payment of severance benefits to affected employees of the Company. The Company granted approximately 151,000 restricted stock units to retained employees with a two year vesting schedule and offered a cash retention bonus of 50% of each retained employees then current base salary, of which $1.5 million was paid in October 2018.

Net Loss per Share of Common St

Net Loss per Share of Common Stock	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Net Loss per Share of Common Stock	12. Net loss per share of Common Stock The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company (in thousands, except per share data): December 31, 2019 2018 Net loss attributable to common stockholders- basic and diluted $ (18,218 ) $ (76,333 ) Net loss per share- basic and diluted $ (1.57 ) $ (10.64 ) Weighted-average common shares used to compute net loss per share- basic and diluted 11,589 7,171 Basic net loss attributable to common stockholders per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and dilutive common stock equivalents outstanding for the period, determined using the treasury-stock method and the as-if converted method, for convertible securities, if inclusion of these is dilutive. Because the Company has reported a net loss for the years ended December 31, 2019 and 2018, the Company did not have dilutive common stock equivalents and therefore diluted net loss per common share is the same as basic net loss per common share for those years. The following potentially dilutive securities outstanding at the end of the years presented have been excluded from the computation of diluted shares outstanding: December 31, 2019 2018 Options to purchase common stock 1,820,160 1,515,923 Restricted stock units 42,112 117,597

Merger with Aravive Biologics,

Merger with Aravive Biologics, Inc.	12 Months Ended
	Dec. 31, 2019
Business Combinations [Abstract]
Merger with Aravive Biologics, Inc.	13. Merger with Aravive Biologics, Inc. On October 12, 2018, pursuant to the terms of the Agreement and Plan of Merger and Reorganization, dated as of June 3, 2018, by and between the Company, then known as Versartis, Inc., Velo Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”), and Private Aravive, Merger Sub was merged with and into Private Aravive (the “Merger”), with Private Aravive surviving the Merger as a wholly-owned subsidiary of the Company. Pursuant to the terms of the Merger Agreement, at the effective time of the Merger or the Effective Time, each outstanding share of capital stock of Private Aravive (other than any shares held as treasury stock) was converted into the right to receive 2.2801 shares of the Company’s common stock, par value $0.0001 per share (the “Company Common Stock”), without giving effect to any adjustment for the reverse stock split described below, and (b) each outstanding Private Aravive stock option, all of which were in-the-money, whether vested or unvested, that had not previously been exercised prior to the Effective Time was converted into an option to purchase 2.2801 shares of the Company Common Stock for each share of Private Aravive common stock covered by such option. The aggregate consideration issued in the Merger to the former security holders of Private Aravive, was 5,141,915 shares of Company Common Stock. The Merger was accounted for as an asset acquisition by the Company. To determine the accounting for this transaction under GAAP, the Company assessed whether an integrated set of assets and activities were accounted for as an acquisition of a business or an asset acquisition. The guidance requires an initial screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single asset or group of similar assets. If that screen is met, the set is not a business. In connection with the acquisition of Private Aravive, the Company determined that substantially all the fair value is included in in-process research and development of Private Aravive’s lead asset, AVB-500 and, as such, the acquisition is treated as an asset acquisition. The net tangible and intangible assets acquired and liabilities assumed in connection with the transaction were recorded based on their relative fair values allocation as of October 12, 2018 and the value associated with in-process research and development will be expensed as it was determined to have no alternative future use the fair value of the identifiable tangible and intangible assets acquired and liabilities assumed, were as follows. Amount (in thousands) Consideration Common stock issued - 5,141,915 shares issued at $7.26 per share $ 37,331 Transaction costs 2,076 Total consideration $ 39,407 Assets acquired and liabilities assumed Cash $ 5,277 In-process research and development 38,313 Assembled workforce 366 Deferred revenue (1,517 ) Contingent payable (264 ) Other assets and liabilities (2,768 ) Total net assets acquired $ 39,407 Corporate Name Change On October 15, 2018, the Company changed its name to “Aravive, Inc.” from Versartis, Inc. Shares of Company Common Stock were previously listed on the Nasdaq Global Select Market under the symbol “VSAR.” The Company filed with The Nasdaq Stock Market, LLC (“Nasdaq”) a notification form for the listing of additional shares with respect to the shares of Company Common Stock to be issued to the holders of Aravive Biologics, Inc. capital stock in the Merger so that these shares are listed on Nasdaq. The Company Common Stock began trading on the Nasdaq Global Select Market under the symbol “ARAV” on October 16, 2018.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events On January 8, 2020 upon the appointment of Ms. Hemrajani as the Company’s President and Chief Executive Officer, Jay Shepard resigned as the Company’s Chief Executive Officer and assumed Chairman of the Board of Directors. On January 9, 2020 the Company entered into a separation agreement with Mr. Shepard along with a consulting agreement. This consulting agreement provides that in consideration for Mr. Shepard providing transition services to the Company, the Company agreed to pay Mr. Shepard $150,000 payable pro-rata on a monthly basis over a six-month period along with reimbursement of all COBRA payments made for the benefits during the consulting period. In March 2020, the Company has decided to amend its clear renal cell carcinoma to initiate treatment at 15 mg/kg or 20 mg/kg given the safety profile seen with the 15 mg/kg dosing cohort of the platinum resistant ovarian cancer (PROC) trial and the recent initiation of the 20 mg/kg dosing cohort in the PROC population. While this may delay first patient dosing, the overall timelines for top line data may not be significantly impacted given the higher starting dose, assuming the COVID-19 situation does not interfere with ongoing clinical studies. Also, to reduce the risk of unnecessary exposure of patients to COVID-19 that may be caused by patients coming to health centers for their AVB-500 intravenous infusion, the Company will pause new enrollment in its IgA nephropathy (IgAN) trial as this is a relatively healthy patient population with a chronic disease . In addition, an outbreak near where our clinical trial sites are located would likely impact our ability to recruit patients, delay our clinical trials, and could affect our ability to complete our clinical trials within the planned time periods. It is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on our business or results of operations at this time.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation and Use of Estimates	Basis of Presentation and Use of Estimates The accompanying consolidated financial statements have been prepared in accordance with GAAP. The preparation of the accompanying consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The accompanying financial statements are consolidated for the years ended December 31, 2019 and 2018 and include the accounts of Aravive, Inc. and its wholly-owned subsidiaries, Versartis Cayman Holdings Company, incorporated in 2014, Versartis GmbH, incorporated in 2015 and Private Aravive, incorporated in 2007. After 2015, the Cayman and GmbH subsidiaries became dormant. In 2019, the Cayman and GmbH subsidiaries were liquidated in their respective countries and no longer exist as of December 31, 2019. All intercompany accounts and transactions have been eliminated. The U.S. dollar is the functional currency for all of the Company's subsidiaries and consolidated operations. Liquidity and Capital Resources Since inception, the Company has incurred net losses and negative cash flows from operations. At December 31, 2019, the Company had an accumulated deficit of $470.1 million and working capital of $63.3 million. Since inception, the Company has incurred net losses and negative cash flows from operations. The Company expects to continue to incur losses from costs related to the development of AVB-500 and related administrative activities for the foreseeable future. As of December 31, 2019, the Company had a cash and cash equivalents balance of $65.1 million consisting of cash and investments in highly liquid U.S. money market funds. While the Company believes that its existing cash and cash equivalents will be sufficient to sustain operations for at least the next 12 months from the issuance of these financial statements, based on its current business plan, the Company will need to obtain additional financing to advance our clinical development program to later stages of development and commercialize our clinical product candidate. Although management has been successful in raising capital in the past, there can be no assurance that the Company will be successful or that any needed financing will be available in the future at terms acceptable to the Company. Correction of Quarterly Information During the fourth quarter ended December 31, 2018, the Company determined that the amount related to the inducement on build-to-suit lease obligation as reflected within one line in the investing activities section of the unaudited consolidated statement of cash flows for the three-, six-, and nine-month periods ended March 31, 2018, June 30, 2018, and September 30, 2018, respectively, filed on Form 10-Q, should have been classified as cash flows provided from financing activities. There is no impact to the consolidated statements of operations and comprehensive loss or consolidated balance sheets for any of these periods. The Company evaluated the effect of this misclassification and concluded it was not material to any of its previously issued unaudited consolidated financial statements. Upon revision, cash flows from investing activities for the three-, six-, and nine-month periods ended March 31, 2018, June 30, 2018, and September 30, 2018, decreased by $1.5 million, $1.9 million, and $1.9 million, respectively and cash flows from financing activities for the respective periods increased by $1.5 million, $1.9 million, and $1.9 million, respectively. This adjustment had no impact to the Company’s financial position, results of operations or cash flows as of and for the year ended December 31, 2018.
Segments	Segments The Company operates in one segment. Management uses one measurement of profitability and does not segregate its business for internal reporting. All long-lived assets are maintained in the United States of America.
Concentration of Credit Risk	Concentration of c r Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. All of the Company’s cash and cash equivalents are held at several financial institutions that management believes are of high credit quality. Such deposits may exceed federally insured limits.
Risks and Uncertainties	Risk and Uncertainties The Company’s future results of operations involve a number of risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company’s potential drug candidates, uncertainty of market acceptance of the Company’s products, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals and sole source suppliers. Products developed by the Company require clearances from the U.S. Food and Drug Administration (“FDA”), the Pharmaceuticals Medicines and Devices Agency (“PMDA”), or other international regulatory agencies prior to commercial sales. There can be no assurance that the products will receive the necessary clearances. If the Company is denied clearance, clearance is delayed or the Company is unable to maintain clearance, it could have a material adverse impact on the Company. The Company expects to incur substantial operating losses for the next several years and will need to obtain additional financing in order to launch and commercialize any product candidates for which it receives regulatory approval.
Cash and Cash Equivalents, Restricted Cash	Cash and c e The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. At December 31, 2019 and 2018 the Company’s cash and cash equivalents were held in multiple institutions within the United States and included deposits in money market funds which were unrestricted as to withdrawal or use. Restricted cash consists of a letter of credit to secure the Company’s obligations under the right-of-use lease.
Property and Equipment, Net	Property and e Property and equipment are stated at cost and depreciated using the straight-line method over the estimated useful lives of the assets, generally between three and five years. Leasehold improvements are amortized on a straight-line basis over the lesser of their useful life or the term of the lease. Maintenance and repairs are charged to expense as incurred, and improvements are capitalized. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the consolidated balance sheets and any resulting gain or loss is reflected in operations in the period realized.
Leases	Leases The Company adopted ASC 842 on January 1, 2019. For the periods prior to January 1, 2019, the Company’s leases were accounted for under ASC 840. The Company leases all of its office space in conducting its business. At inception, the Company determines whether an agreement represents a lease and at commencement the Company evaluates each lease agreement to determine whether the lease is an operating or financing lease. As described below under "Recent Accounting Pronouncements”, the Company adopted the Financial Accounting Standards Board Accounting Standards Update, or ASU, "Leases," or ASU 2016-02. The Company elected to adopt the standard on January 1, 2019 using the alternative transition method provided by ASU 2018-11 whereby the Company recorded right-of-use (“ROU”) assets and lease liabilities for its existing leases as of January 1, 2019, as well as a cumulative-effect adjustment to accumulated deficit of initially applying the new standard as of January 1, 2019. The new standard provides a number of optional practical expedients in transition. The Company has elected the practical expedients to not reassess its prior conclusions about lease identification under the new standard, to not reassess lease classification, and to not reassess initial direct costs. The Company has elected the practical expedient allowing the use-of-hindsight which doesn’t require the Company to reassess the lease term of its leases based on all facts and circumstances through the effective date. The new guidance also provides practical expedients for ongoing lease accounting. The Company has elected the recognition exemption for short-term lease for all leases that qualify. Under this exemption, the Company will not recognize ROU assets or lease liabilities on the consolidated balance sheet for those leases that qualify as a short-term lease, which includes not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in transition. The Company has also elected the practical expedient to not separate lease and non-lease components for all equipment and real-estate leases. With the adoption of ASU 2016-02, the Company recorded an operating lease right-of-use asset and an operating lease obligation on the consolidated balance sheet. ROU assets represent the Company’s ROU of the underlying asset for the lease term and the lease obligation represents the Company’s commitment to make the lease payments arising from the lease. ROU obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term and ROU assets are calculated as the lease liability, adjusted by unamortized initial direct costs, unamortized lease incentives received, cumulative deferred or prepaid lease payments, and accumulated impairment losses. As the Company’s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the adoption date in determining the present value of lease payments. The lease term may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms. Variable lease costs such as common area costs and property taxes are expensed as incurred. Variable lease costs and short-term lease payments not included in the lease liability are classified within operating activities in the consolidated statements of cash flows. For all lease agreements the Company has combined lease and nonlease components. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet. These expenses are recognized within operating expenses in the consolidated statements of operations. The Company accounts for the sublease with EVA as an operating lease. The Company reviews the right-of-use asset recorded associated with the sublease for impairment whenever events or changes in circumstances indicate that the carrying amount of the right-of-use asset may not be recoverable. Recoverability is measured if the lease cost for the term of the sublease exceeds the anticipated sublease income for the same period on an undiscounted basis and the Company shall treat this circumstance as an indicator that the carrying amount of the right-of-use asset may not be recoverable. There have been no such impairments of right-of-use assets during the year ended December 31, 2019. Prior to the Company’s adoption of ASU 2016-02, when the Company’s lease agreements contained renewal options, tenant improvement allowances, rent holidays and rent escalation clauses, the Company recorded a deferred rent asset or liability equal to the difference between the rent expense and the future minimum lease payments due. The lease expense related to operating leases was recognized on a straight-line basis in the consolidated statements of operations over the term of each lease.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by the comparison of the carrying amount to the future net cash flows which the assets are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value (i.e. determined through estimating projected discounted future net cash flows or other acceptable methods of determining fair value) arising from the asset. There have been no such impairments of long-lived assets during the years ended December 31, 2019 and 2018.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The carrying value of the Company’s cash and cash equivalents, restricted cash, accounts payable and accrued liabilities approximate fair value due to the short-term nature of these items. Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a three-level valuation hierarchy for disclosure of fair value measurements as follows: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities; Level 2 Inputs other than quoted prices included within Level 1 that are observable, unadjusted quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and Level 3 Unobservable inputs that are supported by little or no market activity for the related assets or liabilities. The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Company’s financial instruments consist of Level 1 assets as of December 31, 2019 and 2018. Level 1 securities are comprised of highly liquid money market funds.
Preclinical and Clinical Trial Accruals	Preclinical and Clinical Trial Accruals The Company’s clinical trial accruals are based on estimates of patient enrollment and related costs at clinical investigator sites as well as estimates for the services received and efforts expended pursuant to contracts with multiple research institutions and clinical research organizations (“CROs”) that conduct and manage clinical trials on the Company’s behalf. The Company estimates preclinical and clinical trial expenses based on the services performed, pursuant to contracts with research institutions and clinical research organizations that conduct and manage preclinical studies and clinical trials on its behalf. In accruing service fees, the Company estimates the time period over which services will be performed and the level of patient enrollment and activity expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual accordingly. Payments made to third parties under these arrangements in advance of the receipt of the related services are recorded as prepaid expenses until the services are rendered.
Research and Development	Research and d Research and development costs are charged to operations as incurred. Research and development costs include, but are not limited to, payroll and personnel expenses, laboratory supplies, consulting costs, external research and development expenses and allocated overhead, including rent, equipment depreciation, and utilities. Costs to acquire technologies to be used in research and development that have not reached technological feasibility and have no alternative future use are expensed to research and development costs when incurred.
Income Taxes	Income t The Company accounts for income taxes under the asset and liability approach. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. The Company assesses all material positions taken in any income tax return, including all significant uncertain positions, in all tax years that are still subject to assessment or challenge by relevant taxing authorities. Assessing an uncertain tax position begins with the initial determination of the position’s sustainability and is measured at the largest amount of benefit that is greater than percent likely of being realized upon ultimate settlement. As of each balance sheet date, unresolved uncertain tax positions must be reassessed, and the Company will determine whether (i) the factors underlying the sustainability assertion have changed and (ii) the amount of the recognized tax benefit is still appropriate. The recognition and measurement of tax benefits requires significant judgment. Judgments concerning the recognition and measurement of a tax benefit might change as new information becomes available.
Stock-Based Compensation	Stock-Based c For stock options granted to employees, the Company recognizes compensation expense for all stock-based awards based on the grant-date estimated fair value. The value of the portion of the award that is ultimately expected to vest is recognized as expense ratably over the requisite service period. The fair value of stock options is determined using the Black-Scholes option pricing model. The determination of fair value for stock-based awards on the date of grant using an option pricing model requires management to make certain assumptions regarding a number of complex and subjective variables. Stock-based compensation expense related to stock options granted to nonemployees is recognized based on the fair value of the stock options, determined using the Black-Scholes option pricing model, as they are earned. The awards generally vest over the time period the Company expects to receive services from the nonemployee.
Comprehensive Loss	Comprehensive Loss Comprehensive loss is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. Specifically, the Company includes cumulative foreign currency translation adjustments and net unrealized gains. There was no difference between net loss and comprehensive loss for all periods presented.
Net Loss per Share of Common Stock	Net Loss per Share of Common Stock Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period. For purposes of the diluted net loss per share calculation, stock options and restricted stock units are considered to be potentially dilutive securities. Because the Company has reported a net loss for the years ended December 31, 2019 and 2018, diluted net loss per common share is the same as basic net loss per common share for those periods.
In-process Research & Development	In-process Research & Development I n-process research and development, or IPR&D, was recorded at its relative fair value using a discounted cash flow model and was assigned to acquired research and development assets that were not fully developed as of the completion of the Merger. IPR&D acquired in an asset purchase is capitalized on the Company’s consolidated balance sheet at its acquisition-date fair value if the acquired IPR&D has alternative future use. For the IPR&D that was acquired from the Merger it was determined that the IPR&D had no alternative future use and therefore it was expensed immediately following the Merger. Fair value measurement was classified as Level 3 under the fair value hierarchy.
Intangible Assets	Intangible Asset Intangible assets consist of an assembled workforce which was acquired as part of the Merger. Intangible assets with definite lives are amortized based on their pattern of economic benefit over their estimated useful lives and reviewed periodically for impairment. The estimated useful life of the assembled workforce is 3 years.
Revenue Recognition	Revenue Recognition The Company’s sole source of revenue for 2019 and 2018 was grant revenue related to the CPRIT Grant, which is being recognized when qualifying costs are incurred and there is reasonable assurance that the conditions of the award have been met for collection. Proceeds received prior to the costs being incurred or the conditions of the award being met are recognized as deferred revenue until the services are performed and the conditions of the award are met. Funds received are reflected in deferred revenue as a liability until revenue is earned. Grant revenue is recognized when qualifying costs are incurred. As of December 31, 2019, the Company had an unbilled receivable from CPRIT of $1.6 million, which is reflected in prepaid expenses and other current assets on the accompanying consolidated balance sheet. As of December 31, 2018, the Company had deferred revenue of $0.1 million.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board, or FASB, or other standard setting bodies and adopted by us as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective is not expected to have a material impact on the Company’s financial position or results of operations upon adoption. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) As a result of the adoption of ASC 842 on January 1, 2019, the Company derecognized $8.6 million for the existing asset; $7.3 million for the obligation and $1.3 million to the opening balance of the accumulated deficit. The existing asset and obligation on the consolidated balance sheet resulted from the build-to-suit lease arrangement at 1020 Marsh Road, Menlo Park, California or the 1020 Space, which did not meet the criteria for “sale-leaseback” treatment at the time construction was completed in 2017, and the Company has applied the general lessee transition guidance to this lease. Based on the Company’s assessment of the 1020 Space, qualifies as an operating lease under ASC 842. Additionally, as a result of adoption of ASC 842, the Company recognized operating lease ROU assets of approximately $10.4 million, $2.2 million of leasehold improvements, an operating lease obligation of $12.6 million and derecognition of deferred rent of $0.1 million as of January 1, 2019. In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718) - Improvements to Nonemployee Share-Based Payment Accounting . This amendment provides additional guidance related to share-based payment transactions for acquiring goods or services from nonemployees. The guidance will be effective for the Company for fiscal years beginning after December 15, 2018, including the interim periods within that fiscal year. The Company has adopted this new guidance as of January 1, 2019, which had no material impact on the Company’s consolidated financial statements. Not-For-Profit Entities (Topic 958): Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made The Company has adopted this guidance as of January 1, 2019 which had no material impact to its consolidated financial statements. In May 2017, the FASB issued, ASU-2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting . This guidance clarifies when changes to the terms and conditions of share-based awards must be accounted for as modifications. The guidance does not change the accounting treatment for modifications. The guidance, which became effective on January 1, 2018, has not had a material impact on the Company’s consolidated financial statements. In January 2017, the FASB issued, ASU-2017-01, Business Combinations (Topic 805) – Clarifying the Definition of a Business. In November 2016, the FASB issued, ASU-2016-18, Statement of Cash Flows (Topic 230) - Restricted Cash

Balance Sheet Components (Table

Balance Sheet Components (Tables)	12 Months Ended
	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets (in thousands) December 31, 2019 2018 Preclinical and clinical $ 531 $ 416 Lease receivable 900 606 Unbilled receivable from CPRIT 1,604 — Other 44 16 Total $ 3,079 $ 1,038
Property and Equipment, Net	Property and equipment, net (in thousands) December 31, 2019 2018 Equipment and furniture $ 1,442 $ 1,442 Buildings, leasehold and building improvements 2,674 134 4,116 1,576 Less: Accumulated depreciation and amortization (2,308 ) (1,544 ) Property and equipment, net $ 1,808 $ 32
Intangible Asset, Net	Intangible asset, net (in thousands) December 31, 2019 2018 Assembled workforce $ 366 $ 366 366 366 Less: Accumulated amortization (147 ) (25 ) Intangible asset, net $ 219 $ 341
Accrued Liabilities	Accrued liabilities (in thousands) December 31, 2019 2018 Payroll and related $ 1,248 $ 509 Preclinical and clinical 5 563 Professional services 32 — Other 212 293 Total $ 1,497 $ 1,365

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Financial Instruments Measured at Fair Value on Recurring Basis	The following table sets forth the Company’s financial instruments that were measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands): Fair Value Measurements at December 31, 2019 Total Level 1 Assets Money market funds $ 63,691 $ 63,691 Fair Value Measurements at December 31, 2018 Total Level 1 Assets Money market funds $ 48,389 $ 48,389

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Summary of Minimum Lease Payments Under Non-cancelable Operating Leases	As of December 31, 2019, minimum lease payments under non-cancelable operating leases by period were expected to be as follows (in thousands): Year Ending December 31, 2020 $ 2,668 2021 2,618 2022 2,697 2023 2,777 2024 2,373 Total future minimum lease payments 13,133 Less: discount (2,900 ) Total lease liabilities $ 10,233
Minimum Lease Payments Under Non-cancelable Operating Leases	As of December 31, 2018, minimum lease payments under non-cancelable operating leases by period were expected to be as follows (in thousands): Year Ending December 31, 2019 $ 2,652 2020 2,668 2021 2,618 2022 2,697 2023 2,777 Thereafter 2,373 $ 15,785
Schedule of Future Sublease Income Term	Future base rent and additional rent EVA shall pay to the Company over the sublease term as of December 31, 2019, are as follows (in thousands): Year Ending December 31, 2020 $ 2,563 2021 2,628 2022 2,695 2023 2,764 2024 2,355 $ 13,005

Common Stock (Tables)

Common Stock (Tables)	12 Months Ended
	Dec. 31, 2019
Equity [Abstract]
Summary of Reserved Shares of Common Stock for Future Issuances	The Company had reserved shares of common stock for future issuances as follows: December 31, 2019 2018 Issuance of equity based awards under stock plan 1,391,697 1,201,581 Issuance upon exercise of options under stock plan 1,820,160 1,515,923 Issuance of restricted stock units under stock plan 42,112 117,597 Total 3,253,969 2,835,101

Stock Based Awards (Tables)

Stock Based Awards (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Option Activity	Activity under the Company’s stock option plans is set forth below: Weighted Average Weighted Remaining Aggregate Average Contractual Intrinsic Number of Exercise Life Value Shares Price (in years) (in thousands) Balances, January 1, 2018 607,511 $ 81.60 Additional shares authorized — — Assumption of option plans associated with the merger 1,183,950 0.44 Options granted — — Restricted stock units granted — — Options exercised (3,643 ) 9.66 Options cancelled (271,895 ) 80.09 Balances, December 31, 2018 1,515,923 18.65 Additional shares authorized — — Options granted 483,328 5.55 Restricted stock units granted — — Options exercised (39,686 ) 2.40 Options cancelled (139,405 ) 81.33 Balances, December 31, 2019 1,820,160 $ 10.70 6.6 $ 18,957 Vested and expected to vest as of December 31, 2019 1,796,997 $ 10.75 6.6 $ 18,778 Exercisable as of December 31, 2019 1,474,782 $ 11.31 6.0 $ 16,311
Stock Options Outstanding and Exercisable under Stock Option Plans	The following table summarizes information with respect to stock options outstanding and currently exercisable and vested as of December 31, 2019: Options Exercisable Options Outstanding and Vested Weighted Average Weighted Average Remaining Remaining Range of Number Contractual Number Contractual Exercise Prices Outstanding Life (in Years) Outstanding Life (in Years) $0.06-$0.06 86,867 1.5 86,867 1.5 $0.24-$0.24 621,098 5.4 621,098 5.4 $0.66-$0.90 451,632 7.8 451,632 7.8 $3.54-$5.83 385,673 8.8 110,828 8.8 $5.87-$191.76 274,890 5.8 204,357 5.8 1,820,160 1,474,782
Summary of Fair Value of Employee Stock Options	The fair value of employee stock options was estimated using the Black-Scholes model with the following weighted-average assumptions Year Ended December 31, 2019 2018 Expected volatility 111.0 % 132.0 % Risk-free interest rate 2.4 % 3.0 % Dividend yield 0.0 % 0.0 % Expected life (in years) 6.0 3.3
Schedule of Estimated Stock-Based Compensation Expense	Stock-based compensation expense, net of estimated forfeitures, is reflected in the statements of operations as follows (in thousands): Year Ended December 31, 2019 2018 Operating Expenses Research and development $ 347 $ 2,946 General and administrative 3,052 13,193 Total $ 3,399 $ 16,139
Summary of Restricted Stock Activity	A summary of the Company’s restricted stock activity is presented in the following tables: Weighted Average Number of Grant Date Shares Fair Value Restricted Stock Units Unvested at December 31, 2018 117,597 $ 31.37 Granted — — Vested (59,567 ) 31.37 Forfeited/canceled (15,918 ) 27.16 Unvested at December 31, 2019 42,112 $ 32.97

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of Provision (Benefit) for Federal Income Taxes	The provision (benefit) for federal income taxes in 2019 and 2018 is as follows (in thousands): December 31, 2019 2018 Current Federal $ — $ — State — — — — Deferred Federal $ — $ — State — — Total deferred tax expense — — Total income tax expense $ — $ —
Schedule of Income (Loss) Before Income Taxes Attributed to Geographic Locations	December 31, 2019 2018 United States $ (18,218 ) $ (76,256 ) Foreign (0 ) (77 ) Net loss before provision for income taxes $ (18,218 ) $ (76,333 )
Summary of Statutory Federal Tax Rate to Income or Loss before Taxes	Income tax expense (benefit) in 2019 and 2018 differed from the amount expected by applying the statutory federal tax rate to the income or loss before taxes as summarized below: December 31, 2019 2018 Federal tax benefit at statutory rate 21 % 21 % Change in valuation allowance (23 )% 103 % Section 382 limitation — (109 )% Other non-deductible expenses (1 )% (11 )% Stock based compensation (7 )% (4 ) ASC 842 lease accounting 10 % — Total 0 % 0 %
Significant Components of Net Deferred Tax Assets	Significant components of the Company’s net deferred tax assets at December 31, 2019 and 2018 are as follows (in thousands): December 31, 2019 2018 Net operating loss carry forwards $ 5,869 $ 2,335 Research and development tax credits 90 168 Stock based compensation and other 5,099 5,263 Operating lease obligation 2,149 — Total deferred tax assets 13,207 7,766 Less: Valuation allowance (11,326 ) (7,032 ) Deferred tax liabilities (55 ) (734 ) Operating lease right-of-use assets (1,826 ) — Net deferred tax assets $ — $ —
Reconciliation of Amount of Unrecognized Tax Benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands): Amount Balance at January 1, 2018 $ 3,934 Gross increase/ (decrease) related to prior year tax positions (3,934 ) Gross increase related to current year positions 72 Reductions to unrecognized tax benefits related to lapsing statute of limitations — Balance at December 31, 2018 $ 72 Gross increase/ (decrease) related to prior year tax positions (72 ) Gross increase related to current year positions 39 Reductions to unrecognized tax benefits related to lapsing statute of limitations — Balance at December 31, 2019 $ 39

Net Loss per Share of Common _2

Net Loss per Share of Common Stock (Tables)	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Summary of Computation of Basic and Diluted Net Loss Per Share	The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company (in thousands, except per share data): December 31, 2019 2018 Net loss attributable to common stockholders- basic and diluted $ (18,218 ) $ (76,333 ) Net loss per share- basic and diluted $ (1.57 ) $ (10.64 ) Weighted-average common shares used to compute net loss per share- basic and diluted 11,589 7,171
Summary of Potentially Anti-dilutive Securities Excluded from Computation of Diluted Shares Outstanding	The following potentially dilutive securities outstanding at the end of the years presented have been excluded from the computation of diluted shares outstanding: December 31, 2019 2018 Options to purchase common stock 1,820,160 1,515,923 Restricted stock units 42,112 117,597

Merger with Aravive Biologics_2

Merger with Aravive Biologics, Inc. (Tables)	12 Months Ended
	Dec. 31, 2019
Business Combinations [Abstract]
Schedule of Estimate Purchase Price Fair Value Identifiable Tangible and Intangible Assets Acquired and Liabilities Assumed	The estimate of the purchase price for the fair value of the identifiable tangible and intangible assets acquired and liabilities assumed, were as follows. Amount (in thousands) Consideration Common stock issued - 5,141,915 shares issued at $7.26 per share $ 37,331 Transaction costs 2,076 Total consideration $ 39,407 Assets acquired and liabilities assumed Cash $ 5,277 In-process research and development 38,313 Assembled workforce 366 Deferred revenue (1,517 ) Contingent payable (264 ) Other assets and liabilities (2,768 ) Total net assets acquired $ 39,407

Formation and Business of the_2

Formation and Business of the Company - Additional Information (Detail) - USD ($)	Oct. 16, 2018	Jun. 01, 2016	Jul. 31, 2016	Dec. 31, 2019	Dec. 31, 2018
Grant [Line Items]
Revenue from product development award				$ 4,753,000	$ 1,371,000
Common Stock [Member]
Grant [Line Items]
Reverse stock split ratio	1-for-6
Cancer Prevention & Research Institute of Texas [Member]
Grant [Line Items]
Revenue from product development award			$ 20,000,000
Grant termination date		Nov. 30, 2019
Percentage of cash required to raise in matching funds		50.00%
Cash required to raise in matching funds		$ 10,000,000
Term of project during which cash required to raise in matching funds		3 years
Cash required in matching funds raised		$ 10,000,000
Percentage of grant award proceeds required to pay		400.00%
Cancer Prevention & Research Institute of Texas [Member] | Maximum [Member]
Grant [Line Items]
Percentage of grant award proceeds required to pay thereafter until government exclusivity maintained		1.00%
Stanford University [Member] | Maximum [Member]
Grant [Line Items]
Milestone payments upon achievement of clinical and regulatory milestones				$ 1,000,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Detail)	1 Months Ended	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2017	Mar. 31, 2018USD ($)	Jun. 30, 2018USD ($)	Sep. 30, 2018USD ($)	Dec. 31, 2019USD ($)Segment	Dec. 31, 2018USD ($)	Jan. 01, 2019USD ($)
Significant Accounting Policies [Line Items]
Accumulated deficit					$ (470,111,000)	$ (450,565,000)
Working capital					63,300,000
Cash and cash equivalents					65,134,000	56,992,000
Cash flows from investing activities						3,168,000
Cash flows from financing activities					$ 25,250,000	1,948,000
Number of operating segment | Segment					1
Cash and cash equivalents, restricted cash maturity period					Three months or less
Lessee, operating lease, existence of option to extend	true				true
Lessee, operating lease, existence of option to terminate					true
Impairments of right-of-use assets					$ 0
Impairments of long-lived assets					$ 0	0
Estimated useful life of intangible assets					1 year 9 months 18 days
Unbilled receivable					$ 1,604,000
Build-to-suit lease asset						8,651,000
Build-to-suit lease obligation						7,324,000
Operating lease ROU assets					8,697,000
Operating lease obligation					10,233,000
Reclassification of restricted cash					(1,328,000)
Grant [Member] | Cancer Prevention & Research Institute of Texas [Member] | Aravive Biologics [Member]
Significant Accounting Policies [Line Items]
Deferred revenue						$ 100,000
Grant [Member] | Cancer Prevention & Research Institute of Texas [Member] | Aravive Biologics [Member] | Prepaid Expenses and Other Current Assets [Member]
Significant Accounting Policies [Line Items]
Unbilled receivable					$ 1,600,000
Assembled Workforce [Member]
Significant Accounting Policies [Line Items]
Estimated useful life of intangible assets					3 years
Minimum [Member]
Significant Accounting Policies [Line Items]
Property and equipment estimated useful lives					3 years
Maximum [Member]
Significant Accounting Policies [Line Items]
Property and equipment estimated useful lives					5 years
ASU 2016-02 [Member]
Significant Accounting Policies [Line Items]
Operating lease ROU assets							$ 10,400,000
Leasehold improvements							2,200,000
Operating lease obligation							12,600,000
ASU 2016-02 [Member] | Restatement Adjustment [Member]
Significant Accounting Policies [Line Items]
Accumulated deficit							1,300,000
Cash flows from investing activities		$ (1,500,000)	$ (1,900,000)	$ (1,900,000)
Cash flows from financing activities		$ 1,500,000	$ 1,900,000	$ 1,900,000
Deferred rent							(100,000)
ASU 2016-02 [Member] | Restatement Adjustment [Member] | 1020 Marsh Road, Menlo Park, California [Member]
Significant Accounting Policies [Line Items]
Build-to-suit lease asset							(8,600,000)
Build-to-suit lease obligation							$ (7,300,000)
ASU-2016-18 [Member] | Reclassification of Restricted Cash to Cash and Cash Equivalents [Member]
Significant Accounting Policies [Line Items]
Reclassification of restricted cash					$ 2,400,000

Balance Sheet Components - Prep

Balance Sheet Components - Prepaid Expenses and Other Current Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Prepaid Expense And Other Assets [Abstract]
Preclinical and clinical	$ 531	$ 416
Lease receivable	900	606
Unbilled receivable from CPRIT	1,604
Other	44	16
Total	$ 3,079	$ 1,038

Balance Sheet Components - Prop

Balance Sheet Components - Property and Equipment, net (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 4,116	$ 1,576
Less: Accumulated depreciation and amortization	(2,308)	(1,544)
Property and equipment, net	1,808	32
Equipment and Furniture [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	1,442	1,442
Buildings, Leasehold and Building Improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 2,674	$ 134

Balance Sheet Components - Addi

Balance Sheet Components - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Depreciation expense	$ 0.4	$ 1.1
Amortization expense	$ 0.1
Intangible asset useful life	1 year 9 months 18 days

Balance Sheet Components - Inta

Balance Sheet Components - Intangible Asset, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Finite Lived Intangible Assets [Line Items]
Intangible asset, net	$ 219	$ 341
Assembled Workforce [Member]
Finite Lived Intangible Assets [Line Items]
Intangible asset, gross	366	366
Less: Accumulated amortization	(147)	(25)
Intangible asset, net	$ 219	$ 341

Balance Sheet Components - Accr

Balance Sheet Components - Accrued Liabilities (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Payables And Accruals [Abstract]
Payroll and related	$ 1,248	$ 509
Preclinical and clinical	5	563
Professional services	32
Other	212	293
Total	$ 1,497	$ 1,365

Fair Value Measurements - Finan

Fair Value Measurements - Financial Instruments Measured at Fair Value on Recurring Basis (Detail) - Recurring [Member] - Money market funds [Member] - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets, fair value	$ 63,691	$ 48,389
Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets, fair value	$ 63,691	$ 48,389

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Fair Value Disclosures [Abstract]
Transfers within the hierarchy	$ 0	$ 0

Leases - Additional Information

Leases - Additional Information (Detail) $ in Thousands	1 Months Ended			12 Months Ended
	Oct. 31, 2018ft²	Aug. 01, 2018USD ($)	Mar. 31, 2017USD ($)ft²Lease	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Lessee Lease Description [Line Items]
Number of lease renewal option | Lease			1
Rent expense				$ 2,500
Short term and variable lease cost				500
Cash paid for measurement of lease obligations for operating cash flows from operating leases				$ 2,700
Weighted average remaining lease term				4 years 7 months 6 days
Weighted average discount rate				7.75%
Operating lease payments					$ 15,785
Option to extend, existence, operating facility lease			true	true
Property and equipment, net				$ 1,808	32
Build-to-suit obligation					7,324
Build-to-suit related to construction costs incurred					3,500
Build-to-suit rent expense					300
Assets Held under Operating Leases [Member]
Lessee Lease Description [Line Items]
Property and equipment, net					8,900
1020 Space [Member]
Lessee Lease Description [Line Items]
Operating facility lease area | ft²			34,500
Lease commencement date			2017-08
Operating facility lease term			87 months
Lease agreement, one renewal option term			5 years
Lease agreement, additional extended lease term			5 years
Tenant improvement allowance			$ 1,900
Letter of credit to secure lease obligations			2,400
Operating lease payments			$ 20,000
1020 Space [Member] | Sublease Agreement [Member] | EVA Automation, Inc [Member]
Lessee Lease Description [Line Items]
Operating facility lease term		73 months
Sublease commencement date		Oct. 1, 2018
Abatement of base rent lease payment		$ 900
Operating lease abatement term		5 months
Operating lease payments receivable				2,500	$ 600
Cash received from sublease				$ 2,300
1020 Space [Member] | Lease Agreement [Member]
Lessee Lease Description [Line Items]
Operating facility lease term			86 months
Palo Alto, California [Member] | Sublease Agreement [Member]
Lessee Lease Description [Line Items]
Operating facility lease area | ft²	4,240
Lease commencement date	2018-10
Lease expires date	Aug. 31, 2020
1060 Marsh Road [Member]
Lessee Lease Description [Line Items]
Operating facility lease area | ft²			17,400

Leases - Summary of Minimum Lea

Leases - Summary of Minimum Lease Payments Under Non-cancelable Operating Leases (Detail) $ in Thousands	Dec. 31, 2019USD ($)
Leases [Abstract]
2020	$ 2,668
2021	2,618
2022	2,697
2023	2,777
2024	2,373
Total future minimum lease payments	13,133
Less: discount	(2,900)
Operating lease obligation	$ 10,233

Leases - Minimum Lease Payments

Leases - Minimum Lease Payments Under Non-cancelable Operating Leases (Detail) $ in Thousands	Dec. 31, 2018USD ($)
Leases [Abstract]
2019	$ 2,652
2020	2,668
2021	2,618
2022	2,697
2023	2,777
Thereafter	2,373
Total, Future minimum payments	$ 15,785

Leases - Schedule of Future Sub

Leases - Schedule of Future Sublease Income Term (Detail) $ in Thousands	Dec. 31, 2019USD ($)
Leases [Abstract]
2020	$ 2,563
2021	2,628
2022	2,695
2023	2,764
2024	2,355
Total	$ 13,005

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2019USD ($)
Loss Contingencies [Line Items]
Pending or threatened legal proceedings	$ 0
Percentage of contingent cash payment with remainder on future milestone payments	7.50%
Contingent Payable	$ 264,000
Minimum [Member]
Loss Contingencies [Line Items]
Proceeds from future licensing transaction percentage	10.00%

Common Stock - Additional Infor

Common Stock - Additional Information (Detail)	Dec. 02, 2019USD ($)shares	Oct. 16, 2018	Dec. 31, 2019USD ($)shares	Dec. 31, 2019USD ($)shares	Dec. 31, 2018shares
Class Of Stock [Line Items]
Common stock, shares authorized | shares			100,000,000	100,000,000	100,000,000
Voting power per share				One
Common stock, dividends declared				$ 0
Common stock shares issued | shares			3,633,334
Net proceeds from issuance of common stock			$ 25,100,000	25,127,000
Common stock shares issued, value				$ 25,128,000
Board of Director [Member]
Class Of Stock [Line Items]
Common stock shares issued | shares	133,333
Common stock shares issued, value	$ 1,000,000
Common Stock [Member]
Class Of Stock [Line Items]
Reverse stock split ratio		1-for-6
Conversion ratio		0.01667
Common stock shares issued | shares				3,633,334
Common stock shares issued, value				$ 1,000

Common Stock - Summary of Reser

Common Stock - Summary of Reserved Shares of Common Stock for Future Issuances (Detail) - shares	Dec. 31, 2019	Dec. 31, 2018
Class Of Stock [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	3,253,969	2,835,101
Stock Compensation Plan [Member]
Class Of Stock [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	1,391,697	1,201,581
Options to purchase common stock [Member]
Class Of Stock [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	1,820,160	1,515,923
Restricted Stock Units [Member]
Class Of Stock [Line Items]
Common Stock, Capital Shares Reserved for Future Issuance	42,112	117,597

Stock Based Awards - Additional

Stock Based Awards - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Nov. 30, 2019	Dec. 31, 2019	Dec. 31, 2018	Mar. 20, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Intrinsic value of stock option exercised		$ 400,000	$ 0
Stock options granted		483,328
Number of shares reserved		3,253,969	2,835,101
Common stock, voting rights		One
Stock-based compensation expense		$ 3,399,000	$ 16,139,000
Restricted stock unit remaining weighted average period		6 years 7 months 6 days
Employee Stock Purchase Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of common stock issued and outstanding increase annually		1.00%
Number of shares reserved				416
Additional shares issued	2,500	50,000
End date of automatic annual increase of shares reserved for issuance		Jan. 1, 2024
Common stock, voting rights		Immediately after the grant would own stock possessing 5% or more of the total combined voting power or value of our common stock.
Percentage of stock possessing		5.00%
Rights to purchase stock that remains outstanding		$ 25,000
Offerings of purchase periods		27 months
Maximum employee subscription rate		15.00%
Employee Stock Purchase Plan [Member] | Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of purchase price common stock		85.00%
Employee Stock Option [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options vesting period		4 years
Stock options, weighted-average grant date fair value		$ 4.69
Tax benefits realized from options and other share-based payment arrangements		$ 0
Weighted-average remaining vesting period		2 years 9 months 18 days
Unrecognized employee stock-based compensation		$ 2,000,000
Employee Stock Option [Member] | Employee [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted		0
Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense		$ 1,400,000	$ 3,200,000
Approximate compensation expenses		$ 700,000
Restricted stock unit remaining weighted average period		2 years
2019 Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance		1,391,697
Percentage of common stock issued and outstanding increase annually		4.50%
Equity awards, expiration date		Jan. 1, 2029
Equity incentive plan modification, description		The 2019 Plan is a successor to and continuation of all prior plans including the Company’s 2014 Equity Incentive Plan and Private Aravive’s 2017 Equity Incentive Plan and the 2010 Equity Incentive Plan, as amended (Prior Plans).

Stock Based Awards - Summary of

Stock Based Awards - Summary of Stock Options Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Number of shares
Number of Shares, Beginning balance	1,515,923	607,511
Number of Shares, Assumption of option plans associated with the merger		1,183,950
Number of Shares, Options granted	483,328
Number of Shares, Options exercised	(39,686)	(3,643)
Number of Shares, Options cancelled	(139,405)	(271,895)
Number of Shares, Ending balance	1,820,160	1,515,923
Number of Shares, Vested and expected to vest	1,796,997
Number of Shares, Exercisable	1,474,782
Weighted Average Exercise Price
Weighted Average Exercise Price, Beginning balance	$ 18.65	$ 81.60
Weighted Average Exercise Price, Assumption of option plans associated with the merger		0.44
Weighted Average Exercise Price, Options granted	5.55
Weighted Average Exercise Price, Options exercised	2.40	9.66
Weighted Average Exercise Price, Options cancelled	81.33	80.09
Weighted Average Exercise Price, Ending balance	10.70	$ 18.65
Weighted Average Exercise Price, Vested and expected to vest	10.75
Weighted Average Exercise Price, Exercisable	$ 11.31
Weighted Average Remaining Contractual Life (in years)
Weighted Average Remaining Contractual Life (in years)	6 years 7 months 6 days
Weighted Average Remaining Contractual Life, Vested and expected to vest	6 years 7 months 6 days
Weighted Average Remaining Contractual Life, Exercisable	6 years
Aggregate Intrinsic Value, Options outstanding	$ 18,957
Aggregate Intrinsic Value, Vested and expected to vest	18,778
Aggregate Intrinsic Value, Exercisable	$ 16,311

Stock Based Awards - Stock Opti

Stock Based Awards - Stock Options Outstanding and Exercisable under Stock Option Plans (Detail)	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number	1,820,160
Options Exercisable and Vested, Outstanding Number	1,474,782
$0.06 - $0.06 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower Limit | $ / shares	$ 0.06
Range of Exercise Price, Upper Limit | $ / shares	$ 0.06
Options Outstanding, Number	86,867
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	1 year 6 months
Options Exercisable and Vested, Outstanding Number	86,867
Options Exercisable and Vested, Weighted Average Remaining Contractual Life (Years)	1 year 6 months
$0.24-$0.24 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower Limit | $ / shares	$ 0.24
Range of Exercise Price, Upper Limit | $ / shares	$ 0.24
Options Outstanding, Number	621,098
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	5 years 4 months 24 days
Options Exercisable and Vested, Outstanding Number	621,098
Options Exercisable and Vested, Weighted Average Remaining Contractual Life (Years)	5 years 4 months 24 days
$0.66-$0.90 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower Limit | $ / shares	$ 0.66
Range of Exercise Price, Upper Limit | $ / shares	$ 0.90
Options Outstanding, Number	451,632
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	7 years 9 months 18 days
Options Exercisable and Vested, Outstanding Number	451,632
Options Exercisable and Vested, Weighted Average Remaining Contractual Life (Years)	7 years 9 months 18 days
$3.54-$5.83 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower Limit | $ / shares	$ 3.54
Range of Exercise Price, Upper Limit | $ / shares	$ 5.83
Options Outstanding, Number	385,673
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	8 years 9 months 18 days
Options Exercisable and Vested, Outstanding Number	110,828
Options Exercisable and Vested, Weighted Average Remaining Contractual Life (Years)	8 years 9 months 18 days
$5.87-$191.76 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Range of Exercise Price, Lower Limit | $ / shares	$ 5.87
Range of Exercise Price, Upper Limit | $ / shares	$ 191.76
Options Outstanding, Number	274,890
Options Outstanding, Weighted Average Remaining Contractual Life (Years)	5 years 9 months 18 days
Options Exercisable and Vested, Outstanding Number	204,357
Options Exercisable and Vested, Weighted Average Remaining Contractual Life (Years)	5 years 9 months 18 days

Stock Based Awards - Summary _2

Stock Based Awards - Summary of Fair Value of Employee Stock Options (Detail)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Expected volatility	111.00%	132.00%
Risk-free interest rate	2.40%	3.00%
Dividend yield	0.00%	0.00%
Expected life (in years)	6 years	3 years 3 months 18 days

Stock Based Awards - Schedule o

Stock Based Awards - Schedule of Estimated Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 3,399	$ 16,139
Research and development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	347	2,946
General and administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation expense	$ 3,052	$ 13,193

Stock Based Awards - Summary _3

Stock Based Awards - Summary of Restricted Stock Activity (Detail) - Restricted Stock Units [Member]	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Unvested beginning balance | shares	117,597
Number of Shares, Vested | shares	(59,567)
Number of Shares, Forfeited/canceled | shares	(15,918)
Number of Shares, Unvested ending balance | shares	42,112
Weighted Average Grant-Date Fair Value, Unvested beginning balance | $ / shares	$ 31.37
Weighted Average Grant Date Fair Value, Vested | $ / shares	31.37
Weighted Average Grant Date Fair Value, Forfeited/canceled | $ / shares	27.16
Weighted Average Grant Date Fair Value, Unvested ending balance | $ / shares	$ 32.97

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income (Loss) Before Income Taxes Attributed to Geographic Locations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
United States	$ (18,218)	$ (76,256)
Foreign	0	(77)
Net loss before provision for income taxes	$ (18,218)	$ (76,333)

Income Taxes - Summary of Statu

Income Taxes - Summary of Statutory Federal Tax Rate to Income or Loss before Taxes (Detail)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Federal tax benefit at statutory rate	21.00%	21.00%
Change in valuation allowance	(23.00%)	103.00%
Section 382 limitation		(109.00%)
Other non-deductible expenses	(1.00%)	(11.00%)
Stock based compensation	(7.00%)	(4.00%)
ASC 842 lease accounting	10.00%
Total	0.00%	0.00%

Income Taxes - Significant Comp

Income Taxes - Significant Components of Net Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Net operating loss carry forwards	$ 5,869	$ 2,335
Research and development tax credits	90	168
Stock based compensation and other	5,099	5,263
Operating lease obligation	2,149
Total deferred tax assets	13,207	7,766
Less: Valuation allowance	(11,326)	(7,032)
Deferred tax liabilities	(55)	$ (734)
Operating lease right-of-use assets	$ (1,826)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Tax Contingency [Line Items]
Increase (decrease) in valuation allowance	$ 4,300	$ (95,100)
Total gross deferred tax assets	13,207	7,766
Unrecognized tax benefits	39	72	$ 3,934
Decrease in prior year unrecognized tax benefits	$ 72	$ 3,934
Federal tax benefit at statutory rate	21.00%	21.00%
Provisional amount related to re-measurement of deferred tax balance, reduction amount	$ 33,000
Tax Cuts and Jobs Act, Accounting complete	true
Federal [Member]
Income Tax Contingency [Line Items]
Net operating loss carryforwards	$ 27,900
Net operating loss carryforwards not subject to expiration	23,100
Net operating loss carryforwards subject to expire	$ 4,800
Operating loss carryforwards, expiration	Begin to expire in 2037
Federal [Member] | Research and Development Tax Credits [Member]
Income Tax Contingency [Line Items]
Tax credits	$ 90
Tax credit, expiration	Begin to expire in 2037
Previously Reported [Member]
Income Tax Contingency [Line Items]
Increase (decrease) in valuation allowance		$ (3,300)

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Amount of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Beginning Balance	$ 72	$ 3,934
Gross increase/ (decrease) related to prior year tax positions	(72)	(3,934)
Gross increase related to current year positions	39	72
Ending Balance	$ 39	$ 72

Restructuring Plan - Additional

Restructuring Plan - Additional Information (Detail)	Oct. 06, 2017Employee	Oct. 31, 2017shares	Dec. 31, 2019shares	Dec. 31, 2018USD ($)
Restructuring Plan [Member]
Restructuring Cost And Reserve [Line Items]
Restructuring plan effective date		Oct. 20, 2017
Total number of employees reduced | Employee	45
Approximate reduction as a percent of workforce	62.00%
Restructuring plan notification date to affected employees		Oct. 6, 2017
Severance-related charges				$ 4,200,000
Balance amount owed under restructuring activities				0
Restructuring Plan [Member] | General and administrative [Member]
Restructuring Cost And Reserve [Line Items]
Severance-related charges				1,700,000
Restructuring Plan [Member] | Research and development [Member]
Restructuring Cost And Reserve [Line Items]
Severance-related charges				$ 2,500,000
Severance Benefit Plan [Member]
Restructuring Cost And Reserve [Line Items]
Vesting period of shares granted to retained employees		2 years	2 years
Cash retention bonus percentage of each retained employees then current base salary		50.00%	50.00%
Required additional continuing employment period for retained employees		12 months
Severance Benefit Plan [Member] | Restricted Stock Units [Member]
Restructuring Cost And Reserve [Line Items]
Approximate number of shares granted to retained employees | shares		907,000	151,000

Employee Benefit Plans - Additi

Employee Benefit Plans - Additional Information (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Oct. 31, 2017	Dec. 31, 2019	Oct. 31, 2018
Defined Contribution Plan Disclosure [Line Items]
Matching contributions made		$ 0
Cash retention bonus paid			$ 1,500,000
Severance Benefit Plan [Member]
Defined Contribution Plan Disclosure [Line Items]
Vesting period of shares granted to retained employees	2 years	2 years
Cash retention bonus percentage of each retained employees then current base salary	50.00%	50.00%
Severance Benefit Plan [Member] | Restricted Stock Units [Member]
Defined Contribution Plan Disclosure [Line Items]
Approximate number of shares granted to retained employees	907,000	151,000

Net Loss per Share of Common _3

Net Loss per Share of Common Stock - Summary of Computation of Basic and Diluted Net Loss Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Earnings Per Share [Abstract]
Net loss attributable to common stockholders- basic and diluted	$ (18,218)	$ (76,333)
Net loss per share- basic and diluted	$ (1.57)	$ (10.64)
Weighted-average common shares used to compute net loss per share- basic and diluted	11,589	7,171

Net Loss per Share of Common _4

Net Loss per Share of Common Stock - Additional Information (Detail) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Earnings Per Share [Abstract]
Number of dilutive common stock equivalents	0	0

Net Loss per Share of Common _5

Net Loss per Share of Common Stock - Summary of Potentially Anti-dilutive Securities Excluded from Computation of Diluted Shares Outstanding (Detail) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Options to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially Anti-dilutive securities excluded from computation of diluted shares outstanding	1,820,160	1,515,923
Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially Anti-dilutive securities excluded from computation of diluted shares outstanding	42,112	117,597

Merger with Aravive Biologics_3

Merger with Aravive Biologics, Inc. - Additional Information (Detail) - $ / shares	Oct. 12, 2018	Dec. 31, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Common stock, par value		$ 0.0001	$ 0.0001
Aravive Biologics [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Aggregate consideration issuable in merger, shares	5,141,915
Aravive Biologics [Member] | Agreement and Plan of Merger and Reorganization [Member]
Business Acquisition [Line Items]
Common stock, par value	$ 0.0001
Aravive Biologics [Member] | Agreement and Plan of Merger and Reorganization [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Shares issued upon conversion of stock	2.2801
Aggregate consideration issuable in merger, shares	5,141,915

Merger with Aravive Biologics_4

Merger with Aravive Biologics, Inc. - Schedule of Estimate Purchase Price Fair Value Identifiable Tangible and Intangible Assets Acquired and Liabilities Assumed (Detail) - Aravive Biologics [Member] $ in Thousands	Oct. 12, 2018USD ($)
Consideration
Common stock issued - 5,141,915 shares issued at $7.26 per share	$ 37,331
Transaction costs	2,076
Total consideration	39,407
Assets acquired and liabilities assumed
Cash	5,277
Deferred revenue	(1,517)
Contingent payable	(264)
Other assets and liabilities	(2,768)
Total net assets acquired	39,407
In-process research and development [Member]
Assets acquired and liabilities assumed
Acquired identifiable intangible assets at fair value	38,313
Assembled Workforce [Member]
Assets acquired and liabilities assumed
Acquired identifiable intangible assets at fair value	$ 366

Merger with Aravive Biologics_5

Merger with Aravive Biologics, Inc - Schedule of Estimate Purchase Price Fair Value Identifiable Tangible and Intangible Assets Acquired and Liabilities Assumed (Parenthetical) (Detail) - Aravive Biologics [Member] - Common Stock [Member]	Oct. 12, 2018$ / sharesshares
Business Acquisition [Line Items]
Common stock, shares issued | shares	5,141,915
Common stock, value per share | $ / shares	$ 7.26

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail)	Jan. 09, 2020USD ($)
Subsequent Event [Member] | Jay Shepard [Member]
Subsequent Event [Line Items]
Transition services	$ 150,000